

Anticancer Activity of *Angelica dahurica* Used in Traditional Chinese Medicine (TCM) against Human Breast Cancer Cells: Mechanistic Evaluation by Using an Integrated Approach of Network Pharmacology, Computational Molecular Docking and Experimental Assays

Yanqiu Li^{1,#}, Chenhui Zhao^{2,#}, Yanling Ren³, Liping Xie^{4,*}

¹Department of Pharmacy Dispensing, The Fourth Affiliated Hospital of Harbin Medical University, Harbin, Heilongjiang, CHINA.

²Department of General Surgery, Chongqing Western Hospital, Chongqing, CHINA.

³Department of Physical and Chemical Inspection, Jinzhong Center for Disease Control and Prevention, Jinzhong, Shanxi, CHINA.

⁴Department of Pharmacy, Ningde Mindong Hospital affiliated to Fujian Medical University, Fuan, Fujian, CHINA.

*Yanqiu Li and Chenhui Zhao are co-first authors, they contributed equally to this work.

ABSTRACT

Background: Breast Cancer (BC) remains a major global health challenge, necessitating novel treatment approaches to improve therapeutic outcomes. *Angelica dahurica*, a traditional medicinal plant, contains phytochemicals with potential anticancer properties, offering a promising avenue for investigation. **Aim:** This study evaluates the anticancer potential of *Angelica dahurica* extract against BC by integrating *in silico* network pharmacology with *in vitro* experimental validation, focusing on the modulation of key oncogenic targets STAT3, SRC, and MAPK1. **Materials and Methods:** *In silico*, phytochemicals from *Angelica dahurica* were screened using the TCMSP database, with targets predicted via SwissTargetPrediction and SuperPred. BC-related targets from GeneCards were intersected using JVenn. A protein-protein interaction network was constructed with STRING, analyzed in Cytoscape, and key targets identified via cytoHubba. Molecular docking was performed using DockThor, and SRPlot assessed functional relevance. *In vitro*, MCF-7 (BC) and MCF-10 (normal) cell lines underwent MTT cytotoxicity, clonogenic, EdU proliferation, Annexin V/PI apoptosis, and Western blotting assays. **Results:** *In silico* screening filtered 99 phytochemicals to 13, yielding 155 unique targets based on OB \geq 30%, DL \geq 0.18, and Caco-2 filters. From 3,899 BC-related targets, 138 overlapped, with STAT3, SRC, and MAPK1 as central hubs. Docking confirmed sitogluside's strong binding to these targets, with high-affinity binding energies. SRPlot revealed enriched pathways in proliferation and apoptosis. *In vitro*, the extract showed dose-dependent cytotoxicity in MCF-7 cells (40-160 μ g/mL), reducing viability by up to 60%, with minimal MCF-10 toxicity. Clonogenic assays indicated 70% inhibition of colony formation, and EdU assays showed 50% reduction in DNA synthesis. Annexin V/PI staining confirmed 40% apoptosis induction. Western blotting revealed dose-dependent downregulation of STAT3, SRC, and MAPK1, with reductions up to 65%. **Conclusion:** *Angelica dahurica* extract, particularly sitogluside, effectively targets key oncogenic pathways in breast cancer, supporting its potential as a novel therapeutic agent against BC.

Keywords: *Angelica dahurica*, Network-Pharmacology, Breast Cancer, Gene-ontology Enrichment Analysis, Molecular Docking, Cytotoxicity.

Correspondence:

Dr. Liping Xie

Department of Pharmacy, Ningde Mindong Hospital Affiliated to Fujian Medical University, Fuan, Fujian-355000, CHINA.

Email: xielp28970@outlook.com

ORCID: 0009-0005-1154-8527

Received: 16-10-2025;

Revised: 23-01-2026;

Accepted: 05-03-2026.

INTRODUCTION

BC is still among the most common cancers in women globally. In 2024, global estimates indicated that over 2.3 million BC cases were diagnosed annually, with more than 680,000 deaths attributed to the disease.¹ Despite advances in conventional

therapies such as surgery, radiotherapy, and chemotherapy, challenges including drug resistance and adverse side effects necessitate the exploration of novel therapeutic strategies.² Natural products, and in particular Traditional Chinese Medicine (TCM), have gained considerable attention due to their multitarget activities and synergistic effects. TCM has been practiced for millennia, offering a holistic approach to disease management, and its compounds have recently emerged as promising leads in anticancer drug discovery.³

Angelica dahurica, commonly known as Baizhi in Traditional Chinese Medicine, has long been valued for its anti-inflammatory, pain-relieving, and detoxifying properties.⁴



DOI: 10.5530/ijper.20262481

Copyright Information :

Copyright Author (s) 2026 Distributed under Creative Commons CC-BY 4.0

Publishing Partner : Manuscript Technomedia. [www.mstechnomedia.com]

Recent pharmacological examinations have unveiled that its bioactive components may exert antitumor effects, including the stimulation of apoptosis and the suppression of cell growth in different cancer cells.⁵ The diverse phytochemical profile of *Angelica dahurica*-encompassing coumarins, volatile oils, and polysaccharides-provides a unique opportunity to explore its mechanistic role against breast cancer.⁶

Network pharmacology has emerged as an advanced approach to systematically explore the complex interactions between bioactive compounds and biological systems, addressing challenges in understanding their mechanisms.⁷ By integrating bioinformatics with experimental validation, it enables researchers to identify potential targets, elucidate molecular pathways, and uncover synergistic effects often missed in traditional single-target studies. In the context of Traditional Chinese Medicine (TCM), where herbal medicines involve multiple compounds acting on various pathways, this approach is particularly valuable.⁸ It provides a framework to bridge empirical evidence with molecular mechanisms, enhancing the clinical relevance of TCM-based interventions.

Angelica dahurica multifaceted pharmacological profile offers promising avenues for its use as an anticancer agent. Previous studies have suggested that its compounds might interact with key regulatory proteins involved in cell proliferation, apoptosis, and metastasis.^{9,10} Yet, a systematic study combining network pharmacology with *in vitro* validation is necessary to significantly define these interactions.

The integration of computational predictions with experimental validation has not only accelerated drug discovery but also improved our understanding of the mechanistic interplay between natural compounds and cancer biology. This investigation leverages a series of online databases and bioinformatics tools-including the TCMSP (<http://tcmsp-e.com/tcmsp.php>), SwissTargetPrediction (<https://www.swisstargetprediction.ch/>),¹¹ SuperPred (<https://prediction.charite.de/>), GeneCards (<https://www.genecards.org/>),¹² Jvenn (<https://jvenn.toulouse.inrae.fr/>), STRING (<https://string-db.org/>),¹³ SRPlot (<https://www.bioinformatics.com.cn/en>), and DOCKTHOR (<https://dockthor.lncc.br/v2/>)¹⁴ to systematically profile the phytochemicals present in *Angelica dahurica*, predict their molecular targets, and elucidate the potential pathways implicated in breast cancer therapy. These digital resources have been instrumental in enhancing the precision and reproducibility of target identification, allowing for the integration of vast datasets into a coherent pharmacological network. Furthermore, we utilize an integrated experimental approach comprising phytochemical screening, target identification, Protein-Protein Interaction (PPI) network construction, and pathway enrichment analysis, followed by molecular docking to assess binding affinities. This theoretical framework is supported by a range of cell-based assays, including MTT cytotoxicity, colony formation, EdU proliferation, Annexin

V/PI apoptosis, and Western blotting, to experimentally validate the identified hub genes and elucidate their role in the biological activity of the herbal extract (Supplementary Figure 1).

MATERIALS AND METHODS

Phytochemical Screening

The preliminary screening of phytochemicals from *Angelica dahurica* was performed using the TCMSP database. This platform, which offers extensive information on the Absorption, Distribution, Metabolism, and Excretion (ADME) properties of TCM compounds, was employed with stringent filters: oral bioavailability (OB) $\geq 20\%$, Drug-Likeness (DL) ≥ 0.18 , and Caco-2 cell permeability criteria.¹⁵ Caco-2 cell permeability, measured using a human colon carcinoma cell line that mimics the small intestine's epithelial lining, predicts intestinal absorption and oral bioavailability by assessing a compound's ability to cross a polarized monolayer, expressed as the apparent permeability coefficient (Papp, cm/s).

By applying these filters, we curated a subset of compounds with high drug likeness potential.

Target Selection

The selected phytochemicals were then subjected to target prediction using two online platforms: SwissTargetPrediction and SuperPred. Inputting the molecular structures into these platforms generated a list of probable protein targets based on chemical similarity and pharmacophore mapping. A probability filter (≥ 0.75) was applied to ensure high confidence in the predicted targets. Disease-related targets were further refined using the GeneCards database by cross-referencing known breast cancer-associated genes. This integrative approach provided a significant list of candidate targets for subsequent analysis.

PPI Network Generation

Common targets identified from both the compound prediction and disease databases were then visualized using the Jvenn online platform, which facilitated the intersection analysis between the two datasets. The intersecting genes were subsequently entered into the STRING database for PPI (Protein-Protein Interaction) network construction, with a minimum confidence score set at 0.400 to include only reliable interactions. The resulting PPI network was exported and further analyzed using Cytoscape software (v3.10.2). Within Cytoscape, the Cytohubba plugin was applied to identify hub genes based on degree method that are central to the network and potentially critical in modulating effectiveness of *Angelica dahurica* in BC.

Functional Enrichment

The GO and KEGG pathway analyses were accomplished using the SRPlot tool. These analyses enabled the identification of biological processes, molecular functions, and pathways

significantly allied with the predicted targets, thereby providing insight into the mechanisms underlying the herb's anticancer activity.

Molecular Docking

Molecular docking studies were conducted using the DOCKTHOR online tool to evaluate the binding affinity between a top-scoring molecule, Sitogluside, and three key hub proteins: STAT3, SRC, and MAPK1. Protein structures were downloaded from the RCSB-PDB database STAT3 (6nuq), SRC (1yog), and MAPK1 (6nyb) and prepared using Discovery Studio (Dassault Systèmes, Waltham, MA 02451, USA).¹⁶⁻¹⁸ Water molecules were eliminated and missing hydrogen atoms were added using this software. The ligand structure was designed and optimized using ChemDraw (PerkinElmer, Waltham, MA 02451, USA). Docking simulations were performed with flexible parameters for both the ligand and the binding site, ensuring accurate predictions of the interaction energies and binding modes.

Plant Material Extraction

The aerial parts of *Angelica dahurica* were collected, authenticated, and air-dried. The dried material was ground into a fine powder. Soxhlet extraction was then performed using 95% ethanol as the solvent. Approximately 50 g of the powdered plant material was placed in a Soxhlet extractor and refluxed continuously for 3 hr. The extraction was carried out at 78°C, and under decreased pressure, the rotary evaporator was used to concentrate the resultant extract.

Chemicals, Reagents and Equipment

The chemicals and reagents used in the experimental procedures were procured from reputable suppliers. Ethanol (analytical grade) was sourced from Merck (Merck KGaA, Frankfurter Strasse 250, 64293 Darmstadt, Germany). The MTT reagent was obtained from Sigma-Aldrich (Sigma-Aldrich Corporation, 3050 Spruce Street, St. Louis, MO 63103, USA). Cell culture media and supplements were provided by Gibco (Thermo Fisher Scientific, 168 Third Avenue, Waltham, MA 02451, USA). The BioTek ELx800 microplate-reader (BioTek-Instruments, VT 05404, United States) was used to read absorbance. Antibodies used for western blotting, including anti-STAT3, anti-SRC, anti-MAPK1, and HRP-conjugated secondary antibodies, were purchased from Santa Cruz Biotechnology (2701 N. Meridian Blvd, Dallas, TX 75204, USA). The microscopes used were the Nikon Eclipse 80i Microscope (Nikon Corporation, 5-7-1 Shiba, Minato-ku, Tokyo, Japan) and the Carl Zeiss LSM 710 Confocal Microscope (Oberkochen, Germany).

Cell Lines and Culture Conditions

Normal mammary epithelial cells (MCF-10) and breast cancer cells (MCF-7) were obtained from the American Type Culture Collection (ATCC). Cells were cultured in Dulbecco's Modified

Eagle's Medium (DMEM) supplemented with 10% Fetal Bovine Serum (FBS), 100 U/mL penicillin, and 100 µg/mL streptomycin at 37°C in a humidified atmosphere containing 5% CO₂.

MTT Cytotoxicity Assay

The cytotoxic efficiency for *Angelica dahurica* extract was estimated using the MTT assay. Cells were seeded in 96-well plates at a density of 5×10^3 cells per well and allowed to adhere overnight. The extract was then added at concentrations of 0, 20, 40, 80, and 160 µg/mL. After 24 hr of treatment, 20 µL of MTT solution (5 mg/mL in PBS) was added to each well, followed by a further 4 hr of incubation for the plates. The microplate reader measured the absorbance at 570 nm after the formazan crystals were dissolved in 150 µL of DMSO.

Clonogenic Assay

To assess the long-term proliferation and survival in MCF-7 cells, a clonogenic assay was performed. Cells were plated in 6-well plates at low density and treated with the extract at 0, 40, 80, and 160 µg/mL for 24 hr. After treatment, cells were allowed to grow in fresh medium for 14 days. Colonies were fixed with methanol, stained with crystal violet, and imaged using the Nikon Eclipse 80i microscope. Colony counts were done manually, and survival percentages were computed.

EdU Proliferation Assay

To evaluate and quantify MCF-7 cell-proliferation, the EdU test was used. The EdU (5-ethynyl-2'-deoxyuridine) assay measures cell proliferation by detecting DNA synthesis, incorporating EdU, a thymidine analog, into newly synthesized DNA during the S-phase, which is then fluorescently labeled via click chemistry for visualization and quantification using fluorescence microscopy or flow cytometry. Following treatment with 0, 40, 80, and 160 µg/mL of the extract for 24 hr, cells were incubated with EdU for 2 hr. The incorporated EdU was detected using a fluorescent azide according to manufacturer's provided protocol. Fluorescent images were taken with the Carl Zeiss LSM 710 confocal microscope, and the number of cells that took up EdU was measured.

Apoptosis Analysis

DAPI staining: MCF-7 cells were seeded in culture plates and, upon reaching optimal confluence, were subjected to treatment with *Angelica dahurica* extract at various concentrations. Following a 24-hr incubation, the cells were washed with PBS and fixed using 4% paraformaldehyde for 15 min at room temperature to preserve cellular morphology. After fixation, cells were permeabilized with 0.1% Triton X-100 and subsequently incubated with DAPI solution (1 µg/mL) for 10 min in the dark. The staining process allowed for selective binding of DAPI to A-T rich regions of the DNA, enabling the visualization of nuclear morphology under a fluorescence microscope. This experimental setup was designed

to assess apoptotic changes by highlighting nuclear condensation, fragmentation, and other morphological alterations indicative of cell death.

Annexin V/PI Apoptosis Assay: Apoptotic cell death was quantified using Annexin V-FITC/PI staining. MCF-7 cells were treated with the extract at 0, 40, 80, and 160 µg/mL for 24 hr. Cells were then harvested, washed with cold PBS, and resuspended in binding buffer. Annexin V-FITC and PI were added, and samples were incubated in the dark for 15 min at room temperature. Apoptotic cells were analyzed by flow cytometry, and selected fields were imaged using the Nikon Eclipse 80i microscope.

Western Blotting

To validate the expression of hub genes identified through network pharmacology, Western blot analysis was performed. Protein extracts from treated and protease inhibitor-supplemented RIPA buffer were used to prepare untreated MCF-7 cells. After subjecting the proteins to SDS-PAGE separation, the same quantities were transferred to PVDF membranes. Primer antibodies targeting STAT3, SRC, and MAPK1 (1:1000 dilution) were applied to the membranes after blocking with 5% nonfat milk in TBST. The membranes were then left to incubate overnight at 4°C. Densitometry software (ImageJ Software; Version 1.54m) was used to measure the visible bands after they were treated with HRP-conjugated secondary antibodies (1:5000 dilution).

Data Analysis

All experiments were conducted in triplicate, and findings are expressed as mean ± standard deviation. Statistical significance was assessed using one-way ANOVA, followed by post hoc testing, with $*p < 0.05$, $*p < 0.01$ and $*p < 0.001$ being statistically significant. We combined the computer predictions with the experimental results by comparing the molecular docking scores to the changes in hub gene expression measured by Western blotting and cell tests.

RESULTS

Phytochemical Screening and Target Prediction

An initial search of the TCMSP database identified 99 phytochemicals in *Angelica dahurica*. Application of screening criteria- $OB \geq 30\%$, $DL \geq 0.18$, and Caco-2 cell permeability-reduced this list to 13 compounds (Supplementary Table 1). These 13 compounds were then subjected to target prediction using SwissTargetPrediction and SuperPred. By applying a probability threshold of 75% across the two platforms and consolidating duplicate entries, a final set of 155 unique targets was obtained (Supplementary Table 2). In parallel, breast cancer-related targets were retrieved from GeneCards by filtering with a GIFtS score of $\geq 55\%$. The GeneCards Inferred Functionality Score (GIFtS) quantifies the level of functional annotation for a gene in the GeneCards database, reflecting the extent of knowledge about

its functionality. This initial screening yielded 50,000 potential targets, which were narrowed down to 3,899 targets of relevance (Supplementary Table 3). The integration of both phytochemical and disease-specific target profiles established a significant basis for subsequent analyses.

PPI Construction and Hub Gene Identification

The intersection between the 155 phytochemical-related targets and the breast cancer targets (identified from GeneCards) was determined using JVenn, revealing 138 common targets (Figure 1A). These intersecting targets were imported into the STRING database with parameters set for *Homo sapiens* to construct a comprehensive PPI network. Analysis within Cytoscape revealed a network composed of 114 nodes and 293 edges, demonstrating significant connectivity among the targets (Figure 1B). Further analysis using the cytoHubba plugin identified the top 10 hub genes: STAT3, SRC, MAPK1, HSP90AB1, MTOR, HIF1A, NFKB1, JAK2, PIK3CA, and PIK3R1 (Figure 1B), which are potentially crucial in mediating the biological activities of the phytochemicals in a breast cancer context.

Enriched Pathways

The shared targets were further examined through SRPlot online tools to determine their functional and biological relevance (Figure 1C). BP: Enrichment analysis highlighted processes such as peptidyl-serine phosphorylation, response to xenobiotic stimulus, cellular responses to peptides and alcohol, regulation of membrane potential, protein autophosphorylation, and neuron death regulation. CC: Significant terms included glutamatergic synapse, synaptic membrane structures (e.g., membrane raft, microdomain, presynaptic membrane), and specific synaptic specializations. MF: Key functions identified comprised protein serine/threonine kinase activity, phosphoric ester hydrolase activity, p53 binding, DNA-binding transcription factor activity, and histone kinase activity, in addition to neurotransmitter receptor activity. Enriched pathway analysis revealed several signaling routes and biological processes, including: Chemical carcinogenesis via receptor activation, Insulin resistance, EGFR-tyrosine-kinase-inhibitor-resistance, Sphingolipid signalling, Pancreatic cancer, Neurotrophin signaling pathway, Acute-myeloid-leukemia, Chemical carcinogenesis mediated by reactive oxygen species, Prolactin signaling, and pathways related to PD-L1 and PD-1 in cancer (Figure 2A). A combined network for the plant-compounds-targets-pathways was generated to signify the involvement of these compounds in different cellular pathways (Supplementary Figure 2). These conclusions deliver comprehension into the possible mechanisms by which the phytochemicals might exert their anticancer effects.

Molecular Docking Analysis

Using DockThor, docking examinations were conducted to assess the binding capability of phytochemicals produced from plants

against important cancer targets. Among the 13 compounds, Sitogluside emerged as the lead candidate. It demonstrated significant docking scores and molecular interactions with the top three hub proteins-STAT3, SRC, and MAPK1 (Supplementary Table 4 and Figure 2B). These interactions suggest that Sitogluside may effectively modulate pathways critical for tumor progression and may be worth exploring further in terms of experimental verification in breast cancer therapeutics.

MTT Cytotoxicity Assay

Treatment with the *Angelica dahurica* extract resulted in a clear, dose-dependent decrease in cell viability. In MCF-7 cells, significant cytotoxicity was detected starting from 40 $\mu\text{g/mL}$, with progressively lower absorbance values (and hence cell viability)

recorded at 80 $\mu\text{g/mL}$ and 160 $\mu\text{g/mL}$ compared to untreated controls (Figure 3A). The IC_{50} value was found to be 75.2 $\mu\text{g/mL}$. MCF-10 cells demonstrated a more moderate response, indicating selective toxicity toward the cancerous phenotype.

Clonogenic Assay

Short-term exposure (24 hr) to the extract produced a significant, dose-dependent reduction in the long-term clonogenic survival of MCF-7 cells. Post-treatment incubation for 14 days revealed a marked decrease in the number and size of colonies (Figure 3B). At 160 $\mu\text{g/mL}$, the colony formation was substantially inhibited, with survival fractions significantly lower than the control group, indicating strong anti-proliferative effects (Figure 3C).




Figure 1: (A) Venn Diagram of Common Targets: Venn diagram generated using JVenn illustrating the intersection between 155 phytochemical-related targets and breast cancer targets sourced from GeneCards. The diagram shows that 138 common targets were identified, establishing the basis for subsequent network analyses. (B) Protein-Protein Interaction (PPI) Network Visualization: PPI network of the 138 common targets constructed using the STRING database (parameters set for Homo sapiens) and visualized in Cytoscape. This network comprises 114 nodes and 293 edges, reflecting extensive connectivity and the potential functional interplay among the targets. Hub Gene Analysis via cytoHubba: Network analysis using the cytoHubba plugin, highlighting the top 10 hub genes (STAT3, SRC, MAPK1, HSP90AB1, MTOR, HIF1A, NFKB1, JAK2, PIK3CA, and PIK3R1) within the PPI network. These hub genes are posited to play critical roles in the biological activities mediated by the phytochemicals in a breast cancer context. (C) GO Analysis: Graphical representation of GO enrichment analysis performed using SRPlot online tools. Panels depict results for BP, CC, and MF, with significant enrichment in processes such as peptidyl-serine phosphorylation, synaptic membrane architecture, and protein kinase activities.

Apoptosis induction

MCF-7 cells treated with 0- 160 µg/mL of the extract for 24 hr were processed for apoptosis detection. Flow cytometric data revealed a dose-dependent increase in early- and late-apoptotic cells, with significant elevation in Annexin V-positive cells at 80 and 160 µg/mL (Figures 3D and E). The DAPI assay results clearly revealed pronounced nuclear alterations in treated MCF-7 cells compared to control group. Cells exposed to increasing concentrations of the extract exhibited significant chromatin condensation and nuclear fragmentation, indicated by bright, punctate fluorescence patterns (Figure 4A). The intensity and pattern of DAPI fluorescence provided compelling visual evidence supporting the cytotoxic effects observed in the *in vitro* assays, thereby contributing to the overall understanding of the extract’s anti-proliferative mechanism. These nuclear abnormalities corroborated the apoptosis detected through Annexin V/PI staining, reinforcing the conclusion that the *Angelica dahurica* extract effectively induces apoptosis.

EdU Proliferation Assay

In the EdU incorporation assay, a significant reduction in DNA synthesis was observed in MCF-7 cells following extract treatment. Quantitative image analysis showed a progressive decline in the percentage of EdU-positive cells with increasing extract concentrations (40, 80, and 160 µg/mL), confirming impaired cell proliferation in a dose-dependent manner (Figures 4B and C).

Western Blotting Analysis

Western blot analysis targeting key hub proteins identified from network pharmacology (STAT3, SRC, and MAPK1) demonstrated a dose-dependent downregulation in their expression levels in MCF-7 cells (Figure 4D). Densitometric quantification confirmed that the extract treatment significantly reduced protein levels relative to the untreated control, aligning with the observed cellular and molecular effects (Figure 4E).




Figure 2: (A) KEGG Pathway Enrichment Analysis: Visualization of enriched KEGG pathways as Sankey plot derived from the common targets, illustrating multiple significant pathways, including chemical carcinogenesis via receptor activation, insulin resistance, EGFR tyrosine kinase inhibitor resistance, and the PD-1/PD-L1 checkpoint pathway, among others. (B) Molecular Docking of Sitogluside with Hub Proteins: Representative docking poses from DockThor showing the binding interactions between sitogluside and key hub proteins (STAT3 (I), SRC (II), and MAPK1 (III)). The figure highlights significant docking scores and specific molecular interactions that support the compound’s potential inhibitory effects on these targets.




Figure 3: (A) MTT Cytotoxicity Assay: Bar graph depicting the dose-dependent decrease in cell viability of MCF-7 breast cancer cells following treatment with *Angelica dahurica* extract. Viability is significantly reduced at concentrations of 40, 80, and 160 µg/mL compared to the untreated control, with a more moderate effect observed in MCF-10 cells. (B) Clonogenic Assay - Colony Formation: Representative microscopic images showing a marked reduction in colony formation of MCF-7 cells after 24-hr extract exposure followed by 14 days of growth. Fewer and smaller colonies are evident as the extract concentration increases. (C) Clonogenic Assay - Survival Fraction: Quantitative analysis of clonogenic assay results presented as a survival fraction graph. Data indicate a significant, dose-dependent decline in the clonogenic potential of MCF-7 cells upon extract treatment. (D) Annexin V/PI Apoptosis Analysis: It presents the quantitative analysis of early and late apoptotic cell populations. Both panels demonstrate a significant, dose-dependent increase in apoptosis following extract treatment. (E) It shows representative flow cytometry dot plots of Annexin V/PI-stained MCF-7 cells.




Figure 4: (A) DAPI Staining for Nuclear Morphology: Fluorescence images of DAPI-stained MCF-7 cells illustrating pronounced nuclear alterations (chromatin condensation and fragmentation) at escalating extract concentrations. These nuclear changes are indicative of apoptosis. (B and C) EdU Proliferation Assay: Fluorescence microscopy images and corresponding quantification graph depicting a progressive decrease in EdU-positive MCF-7 cells with increasing extract concentrations, indicating substantial suppression of DNA synthesis and cell proliferation. (D) Western Blot Analysis of Hub Protein Expression: Representative Western blot images showing the expression levels of STAT3, SRC, and MAPK1 in MCF-7 cells treated with varying concentrations of *Angelica dahurica* extract. A clear dose-dependent reduction in band intensities is evident compared to the untreated control. (E) Densitometric Quantification of Western Blots: Bar graph representing the densitometric analysis of STAT3, SRC, and MAPK1 protein bands. The data confirm a statistically significant, dose-dependent downregulation of these hub proteins following extract treatment, corroborating the observed *in vitro* effects.


DISCUSSION

The PPI networks are indispensable in network pharmacology for mapping molecular interactions, identifying key targets, and elucidating multi-target mechanisms, particularly for complex herbal medicines. In our *Angelica dahurica* study, the PPI network was critical in identifying STAT3, SRC, and MAPK1 as hub targets, guiding *in silico* predictions and *in vitro* validation, and highlighting the extract's therapeutic promise in breast cancer treatment by disrupting interconnected oncogenic pathways. These proteins serve as pivotal nodes in signalling cascades that regulate cell proliferation, survival, and apoptosis-pathways essential for breast cancer advancement.


Signal-Transducer and Activator of Transcription-3 (STAT3) is pivotal for oncogenesis.¹⁹ The *in silico* network pharmacology method, which combined target prediction with subsequent PPI analysis, revealed STAT3 as a major hub gene. The docking tests, especially with sitogluside-one of the 13 phytochemicals retrieved from the TCMSP database-demonstrated considerable binding affinity to STAT3, indicating that the molecule may

directly interact with and possibly suppress STAT3 activity. The identification aligns with the established function of STAT3 in regulating genes associated with cell survival, proliferation, and inflammation.^{20,21} *In vitro*, Western blot analysis demonstrated a dose-dependent reduction of STAT3 in MCF-7 breast cancer cells after treatment with the extract. The decrease in STAT3 expression corresponded with the cell viability reduction, suppression of colony formation, and initiation of apoptosis. Given that STAT3 is often constitutively active in several malignancies, its downregulation is expected to impair essential survival pathways in tumour cells.²² The reduction of STAT3 activity may result in less transcription of genes that encode anti-apoptotic proteins, thereby making cancer cells more vulnerable to programmed cell death. Furthermore, STAT3 participates in the control of the tumour microenvironment and immune evasion; hence, its suppression may further diminish tumour aggressiveness.

SRC, a non-receptor tyrosine kinase, is a crucial element of carcinogenic signalling networks.^{23,24} SRC, recognised as a hub gene in network pharmacology and PPI analysis, has a pivotal role



Supplementary Figure 1: Flow Diagram showing study plan and execution sequence.



Supplementary Figure 2: Integrated Compound-Target-Pathway Network: Combined network diagram depicting the interactions between plant-derived compounds, identified targets, and enriched signaling pathways. This integrative visualization underscores the multi-target mechanism through which *Angelica dahurica* compounds may exert anticancer effects.

in controlling cell adhesion, migration, and proliferation, making it a significant target in cancer therapies. Molecular docking experiments revealed that sitogluside had a substantial binding affinity with SRC, indicating that it may inhibit SRC's kinase activity. The *in vitro* experiments corroborate this *in silico* as well. The MTT cytotoxicity experiment revealed that treatment with the *Angelica dahurica* extract significantly decreased cell viability, especially in malignant MCF-7 cells relative to MCF-10 cells. This selective toxicity suggests the capacity of the compound to target abnormal signalling pathways exclusive to cancer cells, possibly those driven by SRC. The clonogenic experiment demonstrated a significant decrease in the capacity of MCF-7 cells to form colonies, partially influenced by SRC-mediated signalling that enhances cell survival and proliferation.^{25,26} The extract may inhibit SRC's activity, potentially disrupting downstream signalling pathways that facilitate tumour cell invasion and metastasis, therefore hindering the advancement of breast cancer.

MAPK1, or ERK2, is a pivotal component of the Mitogen-Activated-Protein-Kinase (MAPK) family, essential for the regulation of cell cycle progression, differentiation, and survival.^{27,28} The *in silico* assessment retrieved MAPK1 as a pivotal hub protein within the protein-protein interaction network derived from overlapping targets of phytochemicals and breast cancer-associated genes. Docking simulations demonstrated that sitogluside binds proficiently with MAPK1, suggesting its potential to reduce the enzymatic activity of this kinase and, therefore, diminish the proliferative signals in tumour cells. The EdU incorporation test, used to evaluate cellular proliferation, demonstrated a distinct, dose-dependent reduction in DNA synthesis in MCF-7 cells post-treatment with the extract. The decrease in proliferation is directly associated with the disruption of MAPK1-mediated signalling pathways, since MAPK1 plays a crucial role in conveying mitogenic signals from cell surface receptors to the nucleus.^{29,30} Furthermore, Western blot analysis revealed a substantial reduction in MAPK1 protein levels in treated cells, indicating that the extract not only disrupts the function but also the production of this essential kinase. The cumulative impact of MAPK1 inhibition likely leads to cell cycle arrest and amplifies the pro-apoptotic response shown in the Annexin V/PI apoptosis experiment.

Network pharmacology is crucial in TCM and anticancer drug discovery, providing a holistic framework to analyze the multi-target actions of herbal compounds. Unlike single-target approaches, it integrates bioinformatics and systems biology to map interactions between compounds, genes, and pathways, identifying active constituents, molecular mechanisms, and synergistic effects. In TCM, it connects traditional knowledge with modern insights, accelerating the discovery of effective, low-toxicity anticancer therapies.

The integration of *in silico* predictions and *in vitro* validations reveals that the anticancer efficacy of *Angelica dahurica* extract is facilitated by a coordinated action on STAT3, SRC, and MAPK1. The *in silico* network analysis delineated these proteins as pivotal to the molecular interactions between bioactive chemicals and breast cancer pathogenesis. Subsequent molecular docking experiments demonstrated the ability of sitogluside to bind efficiently with various targets, offering mechanistic insight into how these interactions may result in functional inhibition. The experimental setting demonstrated evident, dose-dependent cytotoxicity of the extract, which inhibited clonogenic potential, indicating a strong antiproliferative action. The reduced proliferation, shown in the EdU test, together with the notable induction of apoptosis shown in the Annexin V/PI assay, further supports the concept that targeting these signalling hubs impairs critical survival pathways in breast cancer cells. The decrease in STAT3, SRC, and MAPK1 protein levels seen in Western blot analyses correlates with the computational predictions and physiological responses, underscoring the translational significance of these targets. These findings together indicate that *Angelica dahurica* extract, particularly its component sitogluside, may serve as a potential therapeutic agent by influencing several carcinogenic pathways.

CONCLUSION

The integrated *in silico* and *in vitro* findings demonstrate that *Angelica dahurica* extract exerts potent anticancer effects against breast cancer by targeting key oncogenic pathways, including STAT3, SRC, and MAPK1. *In silico* network pharmacology and molecular docking identified these proteins as critical targets, supported by *in vitro* assays showing dose-dependent cytotoxicity, reduced proliferation, suppressed clonogenic potential, and enhanced apoptosis in MCF-7 cells. The downregulation of STAT3, SRC, and MAPK1 highlights a multi-target mechanism disrupting vital survival pathways, emphasizing the extract's therapeutic potential for breast cancer treatment, though further preclinical evaluation is warranted.

ACKNOWLEDGEMENT

None.

ABBREVIATIONS

TCMSP: Traditional Chinese Medicine Systems Pharmacology; **ADME:** Absorption, Distribution, Metabolism, and Excretion; **OB:** Oral Bioavailability; **DL:** DrugLikeness; **PPI:** Protein-Protein Interaction; **GO:** Gene Ontology; **KEGG:** Kyoto Encyclopedia of Genes and Genomes; **DMEM:** Dulbecco's Modified Eagle's Medium; **FBS:** Fetal Bovine Serum; **MTT:** 3(4,5Dimethyl thiazol2yl)2,5Diphenyl Tetrazolium Bromide assay; **EdU:** 5Ethynyl2'deoxyuridine; **SDSPAGE:** Sodium Dodecyl Sulfate Polyacrylamide Gel Electrophoresis.

CONFLICT OF INTEREST

The authors declare that there is no conflict of interest.

SUMMARY

The phytochemical study of *Angelica dahurica* yielded 99 different compounds, however only 13 of those compounds exhibited desirable properties such as oral bioavailability ($\geq 30\%$), drug similarity (≥ 0.18), and Caco 2 permeability. Subsequent target prediction across SwissTargetPrediction and SuperPred yielded 155 unique protein targets. Breast cancer-associated targets from GeneCards (GIFTS score $\geq 55\%$) numbered 3,899; their intersection with phytochemical targets comprised 138 shared proteins. These showed a protein-protein interaction network of 114 nodes and 293 edges. Network topology assessment highlighted ten hub genes: STAT3, SRC, MAPK1, HSP90AB1, MTOR, HIF1A, NFKB1, JAK2, PIK3CA, and PIK3R1. Functional enrichment revealed key biological processes-peptidylserine phosphorylation, response to xenobiotic stimulus, cellular responses to peptides and alcohol, regulation of membrane potential, protein autophosphorylation, and neuron death regulation. Cellular component terms included glutamatergic synapse, membrane raft, microdomain, and presynaptic membrane; molecular functions centered on protein serine/threonine kinase activity, phosphoric ester hydrolase activity, p53 binding, DNAbinding transcription factor activity, histone kinase activity, and neurotransmitter receptor activity. Pathway analysis implicated chemical carcinogenesis via receptor activation, insulin resistance, EGFR TKI resistance, sphingolipid signalling, pancreatic cancer, neurotrophin signalling, acute myeloid leukemia, ROS mediated carcinogenesis, prolactin signalling, and PDL1/PD1 pathways. Molecular docking identified Sitogluside with docking scores of -9.092 kcal/mol (STAT3), -7.935 (SRC), and -8.400 (MAPK1). *In vitro*, MCF7 viability decreased significantly from 40 $\mu\text{g/mL}$, with further reductions at 80 and 160 $\mu\text{g/mL}$; clonogenic survival dropped dosedependently, reaching minimal colonies at 160 $\mu\text{g/mL}$. EdU assays showed reduced DNA synthesis at 40, 80, and 160 $\mu\text{g/mL}$. Apoptosis assays revealed increased Annexin V positivity at 80 and 160 $\mu\text{g/mL}$ alongside DAPI detected nuclear fragmentation. Western blots confirmed dosedependent downregulation of STAT3, SRC, and MAPK1, aligning experimental findings with network predictions.








REFERENCES







- Adams M. Epidemiology and the leading causes of death. In: Epidemiology for athletic trainers. Routledge; 2024: 3-19. doi: 10.4324/9781003523994-2.
- Burguin A, Diorio C, Durocher F. Breast cancer treatments: updates and new challenges. *J Pers Med*. 2021;11(8):808. doi: 10.3390/jpm11080808, PMID 34442452.
- Liu S, Zhu JJ, Li JC. The interpretation of human body in traditional Chinese medicine and its influence on the characteristics of TCM theory. *Anat Rec (Hoboken)*. 2021;304(11):2559-65. doi: 10.1002/ar.24643, PMID 34117702.
- Zhao H, Feng YL, Wang M, Wang JJ, Liu T, Yu J. The *Angelica dahurica*: a review of traditional uses, phytochemistry and pharmacology. *Front Pharmacol*. 2022;13:896637. doi: 10.3389/fphar.2022.896637, PMID 35847034.
- Wang Q, Li Y, Wang S, Xiang Z, Dong W, Li X, et al. A review of the historical records, chemistry, pharmacology, pharmacokinetics and edibility of *Angelica dahurica*. *Arab J Chem*. 2023;16(8):104877. doi: 10.1016/j.arabj.2023.104877.
- Shi H, Chang YQ, Feng X, Yang GY, Zheng YG, Zheng Q, et al. Chemical comparison and discrimination of two plant sources of *Angelicae dahuricae* Radix, *Angelica dahurica* and *Angelica dahurica* var. *formosana*, by HPLC-Q/TOF-MS and quantitative analysis of multiple components by a single marker. *Phytochem Anal*. 2022;33(5):776-91. doi: 10.1002/pca.3129, PMID 35470493.
- Zhao L, Zhang H, Li N, Chen J, Xu H, Wang Y, et al. Network pharmacology, a promising approach to reveal the pharmacology mechanism of Chinese medicine formula. *J Ethnopharmacol*. 2023;309:116306. doi: 10.1016/j.jep.2023.116306, PMID 36858276.
- Zhang P, Zhang D, Zhou W, Wang L, Wang B, Zhang T, et al. Network pharmacology: towards the artificial intelligence-based precision traditional Chinese medicine. *Brief Bioinform*. 2023;25(1):bbad518. doi: 10.1093/bib/bbad518, PMID 38197310.
- Zheng YM, Shen JZ, Wang Y, Lu AX, Ho WS. Anti-oxidant and anti-cancer activities of *Angelica dahurica* extract via induction of apoptosis in colon cancer cells. *Phytomedicine*. 2016;23(11):1267-74. doi: 10.1016/j.phymed.2015.11.008, PMID 26776960.
- Luo KW, Sun JG, Chan JY, Yang L, Wu SH, Fung KP, et al. Anticancer effects of imperatorin isolated from *Angelica dahurica*: induction of apoptosis in HepG2 cells through both death-receptor- and mitochondria-mediated pathways. *Chemotherapy*. 2011;57(6):449-59. doi: 10.1159/00031641, PMID 22189406.
- Bugnon M, Röhrig UF, Goullieux M, Perez MA, Daina A, Michielin O, et al. SwissDock 2024: major enhancements for small-molecule docking with Attracting Cavities and AutoDock Vina. *Nucleic Acids Res*. 2024; 52(W1):W324-32. doi: 10.1093/nar/gkac300, PMID 38686803.
- Stelzer G, Rosen N, Plaschkes I, Zimmerman S, Twik M, Fishilevich S, et al. The GeneCards suite: from gene data mining to disease genome sequence analyses. *Curr Protoc Bioinformatics*. 2016;54(1):1.30.1-1.30.33. doi: 10.1002/cpbi.5, PMID 27322403.
- Szklarczyk D, Kirsch R, Koutrouli M, Nastou K, Mehryary F, Hachilif R, et al. The STRING database in 2023: protein-protein association networks and functional enrichment analyses for any sequenced genome of interest. *Nucleic Acids Res*. 2023; 51(D1):D638-46. doi: 10.1093/nar/gkac1000, PMID 36370105.
- Guedes IA, Pereira da Silva MM, Galheigo M, Krempser E, de Magalhães CS, Correa Barbosa HJ, et al. DockThor-V5: a free platform for receptor-ligand virtual screening. *J Mol Biol*. 2024;436(17):168548. doi: 10.1016/j.jmb.2024.168548, PMID 39237203.
- Mi B, Li Q, Li T, Marshall J, Sai J. A network pharmacology study on analgesic mechanism of Yuanhu-Baizhi herb pair. *BMC Complement Med Ther*. 2020;20(1):284. doi: 10.1186/s12906-020-03078-0, PMID 32948176.
- Bai L, Zhou H, Xu R, Zhao Y, Chinnaswamy K, McEachern D, et al. A potent and selective small-molecule degrader of STAT3 achieves complete tumor regression *in vivo*. *Cancer Cell*. 2019;36(5):498-511.e17. doi: 10.1016/j.ccell.2019.10.002, PMID 31715132.
- Breitenlechner CB, Kairies NA, Honold K, Scheiblich S, Koll H, Greiter E, et al. Crystal structures of active SRC kinase domain complexes. *J Mol Biol*. 2005;353(2):222-31. doi: 10.1016/j.jmb.2005.08.023, PMID 16168436.
- Park E, Rawson S, Li K, Kim BW, Ficarro SB, Pino GG, et al. Architecture of autoinhibited and active BRAF-MEK1-14-3-3 complexes. *Nature*. 2019;575(7783):545-50. doi: 10.1038/s41586-019-1660-y, PMID 31581174.
- Hu Y, Dong Z, Liu K. Unraveling the complexity of STAT3 in cancer: molecular understanding and drug discovery. *J Exp Clin Cancer Res*. 2024;43(1):23. doi: 10.1186/s13046-024-02949-5, PMID 38245798.
- Dinakar YH, Kumar H, Mudavath SL, Jain R, Ajmeer R, Jain V. Role of STAT3 in the initiation, progression, proliferation and metastasis of breast cancer and strategies to deliver JAK and STAT3 inhibitors. *Life Sci*. 2022;309:120996. doi: 10.1016/j.lfs.2022.120996, PMID 36170890.
- Huang B, Lang X, Li X. The role of IL-6/JAK2/STAT3 signaling pathway in cancers. *Front Oncol*. 2022;12:1023177. doi: 10.3389/fonc.2022.1023177, PMID 36591515.
- Sadrkhanloo M, Entezari M, Oroui S, Ghollasi M, Fathi N, Rezaei S, et al. STAT3-EMT axis in tumors: modulation of cancer metastasis, stemness and therapy response. *Pharmacol Res*. 2022;182:106311. doi: 10.1016/j.phrs.2022.106311, PMID 35716914.
- Wang HQ, Man QW, Huo FY, Gao X, Lin H, Li SR, et al. STAT3 pathway in cancers: past, present, and future. *Med*. 2022;3(2):e124. doi: 10.1002/mco.2.124, PMID 35356799.
- Pelaz SG, Taberero A. Src: coordinating metabolism in cancer. *Oncogene*. 2022;41(45):4917-28. doi: 10.1038/s41388-022-02487-4, PMID 36217026.
- Luo J, Zou H, Guo Y, Tong T, Ye L, Zhu C, et al. SRC kinase-mediated signaling pathways and targeted therapies in breast cancer. *Breast Cancer Res*. 2022;24(1):99. doi: 10.1186/s13058-022-01596-y, PMID 36581908.
- Li L, Deng CX, Chen Q. SRC-3, a steroid receptor coactivator: implication in cancer. *Int J Mol Sci*. 2021;22(9):4760. doi: 10.3390/ijms22094760, PMID 33946224.
- Wang Y, Guo Z, Tian Y, Cong L, Zheng Y, Wu Z, et al. MAPK1 promotes the metastasis and invasion of gastric cancer as a bidirectional transcription factor. *BMC Cancer*. 2023;23(1):959. doi: 10.1186/s12885-023-11480-3, PMID 37817112.
- Lu M, Gao Q, Wang Y, Ren J, Zhang T. LINC00511 promotes cervical cancer progression by regulating the miR-497-5p/MAPK1 axis. *Apoptosis*. 2022;27(11-12):800-11. doi: 10.1007/s10495-022-01768-3, PMID 36103025.

29. Petrosino M, Novak L, Pasquo A, Turina P, Capriotti E, Minicozzi V, *et al.* The complex impact of cancer-related missense mutations on the stability and on the biophysical and biochemical properties of MAPK1 and MAPK3 somatic variants. *Hum Genomics*. 2023;17(1):95. doi: 10.1186/s40246-023-00544-x, PMID 37891694.
30. Li M, Cai O, Yu Y, Tan S. Paeonol inhibits the malignancy of Apatinib-resistant gastric cancer cells via LINC00665/miR-665/MAPK1 axis. *Phytomedicine*. 2022;96:153903. doi: 10.1016/j.phymed.2021.153903, PMID 35026514.

Cite this article: Li Y, Zhao C, Ren Y, Xie L. Anticancer Activity of *Angelica dahurica* Used in Traditional Chinese Medicine (TCM) against Human Breast Cancer Cells: Mechanistic Evaluation by Using an Integrated Approach of Network Pharmacology, Computational Molecular Docking and Experimental Assays. *Indian J of Pharmaceutical Education and Research*. 2026;60(3):1131-42.

Supplementary Table 1: Bioactive phytochemicals of *Angelica dahurica* retrieved from the TCMSP database which survived screening criteria.

| Mol ID | Molecule Name | OB (%) | DL | Structure | Smile |
|-----------|-------------------------|--------|------|-------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------|
| MOL001575 | cedryl acetate | 53.94 | 0.17 |  | <chem>C[C@@H]1CC[C@@H]2[C@]13CC[C@@]([C@H](C3)C2(C)C)(C)OC(=O)C</chem> |
| MOL001941 | imperatorin | 34.55 | 0.22 |  | <chem>CC(=CCOC1=C2C(=CC3=C1OC=C3)C=CC(=O)O2)C</chem> |
| MOL001942 | Isoimperatorin | 45.46 | 0.23 |  | <chem>CC(=CCOC1=C2C=CC(=O)OC2=CC3=C1C=CO3)C</chem> |
| MOL001944 | Marmesin | 50.28 | 0.18 |  | <chem>CC(C)([C@@H]1CC2=C(O1)C=C3C(=C2)C=CC(=O)O3)O</chem> |
| MOL003561 | Isopimpinellin | 25.93 | 0.17 |  | <chem>COC1=C2C=COC2=C(C3=C1C=CC(=O)O3)OC</chem> |
| MOL000357 | Sitogluside/Daucosterol | 20.63 | 0.62 |  | <chem>CC[C@H](CC[C@@H](C)[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CC=C4[C@@]3(CC[C@@H](C4)O[C@H]5[C@@H]([C@@H]([C@@H]([C@H](O5)CO)O)O)O)C)C)C)C</chem> |
| MOL000358 | Beta-sitosterol | 36.91 | 0.75 |  | <chem>CC[C@H](CC[C@@H](C)[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CC=C4[C@@]3(CC[C@@H](C4)O)C)C)C)C</chem> |

| Mol ID | Molecule Name | OB (%) | DL | Structure | Smile |
|-----------|-----------------------|--------|------|-------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------|
| MOL003608 | O-Acetylcolumbianetin | 60.04 | 0.26 |  | <chem>CC(=O)OC(C)(C)[C@@H]1CC2=C(O1)C=CC3=C2OC(=O)C=C3</chem> |
| MOL003609 | Columbianetin | 32.11 | 0.17 |  | <chem>CC(C)([C@@H]1CC2=C(O1)C=CC3=C2OC(=O)C=C3)O</chem> |
| MOL004777 | Angelol D | 34.85 | 0.34 |  | <chem>C/C=C(\C)/C(=O)OC(C(C1=C(C=C2C(=C1)C=CC(=O)O2)OC)O)(C(C)C)O</chem> |
| MOL004778 | Angelol G | 46.03 | 0.34 |  | <chem>C/C=C(/C)/C(=O)O[C@H](C1=C(C=C2C(=C1)C=CC(=O)O2)OC)[C@H](C(C)C)O</chem> |
| MOL004780 | Angelicone | 30.99 | 0.19 |  | <chem>CC(=CC(=O)C1=C(C=C(C2=C1OC(=O)C=C2)OC)OC)C</chem> |
| MOL004792 | nodakenin | 57.12 | 0.68 |  | <chem>CC(C)([C@H]1CC2=C(O1)C=C3C(=C2)C=CC(=O)O3)O[C@H]4[C@@H]([C@H]([C@@H]([C@H](O4)CO)O)O)O</chem> |

Supplementary Table 2: Predicted targets of 13 active compounds from *Angelica dahurica* identified using SwissTargetPrediction and SuperPred ($\geq 75\%$ probability).

| APEX1 | PARP2 | UGT2B7 | KDM1A | HDAC2 | RPS6KA3 |
|--------|----------|---------|----------|--------|----------|
| CLK4 | TNKS2 | ACACA | NTRK3 | DPP9 | ADORA2B |
| TRIM24 | TNKS | ACACB | AR | KCNA5 | ADORA3 |
| ALOX12 | PDE9A | GPR35 | FPR2 | CHUK | PRKCG |
| TDP1 | PDE10A | PSMB1 | PSMB2 | MAOA | PRKCA |
| TOP2A | GSK3B | MTNR1B | AKR1C3 | KCNA3 | ABL1 |
| CTSD | MAPK8 | SRC | KCNH2 | BACE1 | PARP1 |
| DUSP3 | ADORA2A | TGFBR1 | HDAC8 | CYP1A2 | MAPKAPK2 |
| KLF5 | HSD17B10 | PIM1 | ITK | GABRB3 | CSNK1G1 |
| NFE2L2 | GLRA1 | PIM2 | ESR2 | SRD5A1 | CHRM1 |
| HIF1A | CNR2 | CA1 | STAT3 | CA12 | KIF11 |
| SLC2A1 | PRCP | ALPL | MTOR | ALOX5 | ADAM10 |
| SLC6A5 | HTR2C | AURKB | PRKCD | MAOB | CHRM4 |
| NR1I2 | CCR1 | AURKA | BLM | ALOX15 | IL2 |
| NFKB1 | MDM4 | JAK1 | CDK1 | CD38 | BCL2L1 |
| DPP8 | FPR1 | JAK2 | IDO1 | CA7 | PSEN2 |
| CSNK2B | C5AR1 | PIK3CA | CYP3A4 | CA14 | PTAFR |
| PDE3A | DPP4 | RPS6KA1 | S1PR5 | CA13 | S1PR3 |
| GPR55 | DPP7 | TNIN | HSP90AB1 | CA5B | S1PR1 |
| RORB | CACNA1B | QRFPR | PIK3R1 | CBR1 | PTPN2 |
| METAP2 | GPBAR1 | PPP2R5A | SCN2A | PIK3CD | CDC25B |
| PDE4D | ADORA1 | HSD11B2 | FPR3 | MAPK1 | ACPI |
| CA9 | PTGS1 | DRD4 | ACHE | ANPEP | PPM1B |
| FLT3 | NR3C2 | RBP4 | PTPN1 | CYP1A1 | PPP1CC |
| MTNR1A | GRIN1 | PFKFB3 | CDC25A | CA2 | PPP2CA |
| CFTR | ITGB1 | GPR6 | GRM5 | CDK5 | |

Supplementary Table 3: Breast cancer-related targets retrieved from GeneCards database filtered by GIFTS score $\geq 55\%$.

| BRCA2 | AURKB | AMACR | IRF8 | CUL2 | PGM3 | UGT8 | SLC26A3 |
|---------|---------|----------|----------|----------|----------|-----------|----------|
| BRCA1 | EPAS1 | AZGP1 | RPS27 | ARHGDIB | SFTPD | MCOLN1 | CHRNA1 |
| ATM | APOB | CTSL | ICOS | TNFRSF17 | ATXN2 | GABARAPL2 | FGG |
| PALB2 | HSPA5 | EED | STRADA | BMX | SGPL1 | TDO2 | NDUFA12 |
| BRIP1 | TLR2 | KLK2 | CTBP2 | BANF1 | LAMA4 | CAMK4 | SGCE |
| CHEK2 | PLCG1 | CASP2 | ACVR2A | PLD1 | ATP5F1B | TBC1D4 | TUB |
| BARD1 | LGALS3 | EIF2AK2 | RAD17 | NID1 | PHF8 | CHRNA2 | EARS2 |
| CDH1 | HSPA4 | PLG | CDK9 | BMP1 | GNAI2 | MICU1 | MINK1 |
| TP53 | NRP1 | CDH11 | GLUL | IL12A | OAS1 | GGCX | ACACB |
| MSH6 | GNRHR | MAP2K3 | TYRP1 | UGT1A6 | PIBF1 | NPEPPS | NDST1 |
| MSH2 | SGK1 | DVL1 | PRKAB1 | FOXO4 | ADH1A | F8 | SLC9A3 |
| MLH1 | EPHA3 | MYH7 | F2 | GLUD1 | LIPE | PCYT1A | HIBCH |
| APC | FGF4 | F2RL1 | PPP5C | MB | NOP56 | ACADM | PHEX |
| PMS2 | DDR2 | XPO1 | RPL15 | ALOX15 | GLRX | PYGB | APBB1 |
| PTEN | PROM1 | MAPK7 | FLI1 | MFN2 | CACNA1H | GJB6 | SLC25A12 |
| EGFR | TMPRSS2 | PGF | EPHA7 | GFRA1 | PDX1 | ACSL1 | GRHPR |
| RAD50 | TRRAP | POLH | ALDH9A1 | PTPRO | DGKE | HCN1 | AMPD2 |
| NF1 | SHBG | COPS5 | ADM | IRF6 | C5 | NSF | PLA2G1B |
| RAD51C | IRS2 | IL1R1 | SPTAN1 | CD38 | CSPG4 | APOL1 | CALB1 |
| ERBB2 | CD36 | CEACAM1 | SIRT6 | CTPS1 | PTX3 | LIPC | TNR |
| NBN | RUNX3 | VCL | DNM2 | PSEN1 | F13A1 | PSMB7 | DRD5 |
| POLD1 | ADIPOQ | OTC | RAN | ANGPTL4 | SOX6 | DCT | CRB1 |
| POLE | KCNH2 | SOS2 | MDK | SCD | UBE2L3 | IL10RB | RDH12 |
| STK11 | ARAF | NAMPT | STAT4 | KIF2C | GALNS | GDF5 | SCN1B |
| AXIN2 | NOS3 | GLA | SCN11A | SOX17 | RFC2 | ATP5PO | CSNK1G1 |
| ESR1 | FGF8 | FGF19 | RPS24 | ECE1 | POLR3A | PEX5 | CHRNA4 |
| PIK3CA | CYP3A4 | GHR | FCGR1A | IFNAR1 | DHX16 | FAM20C | CACNB2 |
| CDKN2A | FOXP3 | CSNK2A2 | CD151 | CDK10 | STT3A | CORO1A | UQCRB |
| MUTYH | KIF1B | LATS2 | SNCA | EIF4A2 | PSMB4 | KLKB1 | GYPA |
| KRAS | HLA-A | CHKA | SOCS2 | MAFB | MAPK8IP1 | MC4R | HAVCR1 |
| MET | LIG4 | CD40LG | MBL2 | SORT1 | CS | CAMK2B | MTTP |
| AKT1 | TNFRSF8 | MCM2 | LGMN | MRAS | SLC25A5 | GRM6 | SARM1 |
| BLM | IL1A | TACSTD2 | SMARCC2 | ANTXR1 | ITPR2 | DTNBP1 | PISD |
| RET | XRCC6 | ADAM15 | IGF2BP2 | PLAGL1 | GNAI3 | ACO1 | ABCG5 |
| RB1 | JAK3 | ELK1 | SERPINF1 | PPP1CA | YWHAH | TNIK | HAAO |
| DICER1 | UGT1A1 | ACP3 | SMAD6 | FBP1 | TECR | GNAO1 | INVS |
| SMAD4 | CDC42 | UBE2T | PODXL | EGR2 | RNASET2 | SLC19A2 | NDUFB8 |
| TSC2 | BCL10 | GRPR | RAG1 | NEDD4L | EOMES | PNPLA2 | GRIA1 |
| MRE11 | MMP11 | NUMB | BRD3 | FTH1 | UBB | MYO1E | HAL |
| SMARCA4 | SULT1A1 | LRP1 | RSPO1 | CACNA1G | PSMA4 | PPP4C | MSTN |
| BAP1 | PAK4 | PPARGC1A | FOXA2 | TFAP2B | PLCB2 | CNTN6 | CHIT1 |
| PTCH1 | HMGB1 | AKAP13 | TAF15 | S1PR1 | SH2D1A | MASP1 | ADAMTS2 |
| KIT | CDC25C | AGTR1 | CALCR | CCR3 | CHRNA7 | SLC8A1 | SCN1A |

| BRCA2 | AURKB | AMACR | IRF8 | CUL2 | PGM3 | UGT8 | SLC26A3 |
|--------|---------|---------|----------|----------|----------|----------|----------|
| BRAF | GNAQ | FOSL2 | CFL1 | ADCYAP1 | YWHAG | IDE | HRG |
| MSH3 | ING1 | RARG | GATA6 | SETD7 | ATP6V1B2 | B4GALNT1 | CES1 |
| EPCAM | CYP2A6 | KISS1R | SELL | KIF23 | ATP2B1 | VAMP1 | MOCS2 |
| FANCC | HDAC9 | PIK3C3 | PDE11A | TLR8 | GRIP1 | CDC34 | GAP43 |
| ALK | BCL2L11 | EDN1 | UBE3A | SOX3 | KRT16 | PEX1 | KCNA1 |
| BMPR1A | BRD4 | CCNH | FSHR | EGLN2 | ATN1 | PIKFYVE | FARS2 |
| TSC1 | KDM1A | HLA-C | PYCR1 | TBX2 | PPP1R12A | NFATC4 | GUCY1A1 |
| CDK4 | ROBO1 | DMD | MAD2L2 | DYRK1B | DNASE1L3 | NLGN4X | PLTP |
| CTNNB1 | FGF10 | CDH17 | PLA2G10 | CYSLTR2 | LTBP3 | BAMBI | CRLF1 |
| AR | NR3C1 | DDX3X | PLK3 | ARHGEF12 | CAMK2D | GOT1 | NDUFS7 |
| CCND1 | EZR | NFATC1 | POLR2A | SOAT1 | CTSH | CYC1 | PPM1A |
| MEN1 | KRT14 | CASP1 | PDIA3 | KIF5B | NAGLU | GALK1 | CLPP |
| CTNNA1 | BMP2 | FBLN1 | NFIX | DOCK8 | ARHGEF7 | LGI1 | COQ6 |
| SDHA | CHD1 | HSD3B2 | UGT1A9 | NISCH | NR2E3 | ALDH1B1 | P2RY6 |
| FGFR2 | ALDH2 | EPO | ATG7 | IL18R1 | TJP2 | LBP | PIGK |
| FH | BECN1 | SLC7A11 | NOD2 | CNR1 | RHOH | ATP1A3 | ABCC9 |
| TERT | HLA-B | HSPD1 | KCNB2 | THBD | PAK2 | PKN2 | SLC39A14 |
| MYC | PAX8 | PTPA | HYAL2 | ADCY10 | OSMR | HJV | WARS2 |
| SDHB | CFLAR | SREBF1 | ITGB6 | MEF2C | FRK | PTPRB | APCS |
| ATR | PRSS1 | WNT2 | BRD2 | S1PR3 | CYP26A1 | SMS | LSS |
| RAD51 | BCL6 | RPS27A | COX5A | PTRH2 | SLC46A1 | KCNJ3 | LINGO1 |
| PDGFRA | CALR | ARID1B | ARRB1 | HNMT | RAB23 | CHMP2B | PDE3B |
| HRAS | CTTN | MAPK12 | HDAC7 | STAG3 | SEC31A | ADORA1 | KCNB1 |
| FLCN | FGF1 | ATP2B4 | PC | HMGB2 | ADCY5 | STAMBP | EBP |
| NTHL1 | TNFSF11 | MFGE8 | RBPJ | STEAP3 | TTPA | SLC38A1 | TNNI2 |
| CDKN1B | CTNND1 | ASXL1 | TNK2 | PLXNA1 | HCK | COL11A2 | NEFM |
| FANCM | NFKB2 | KAT2B | TNFRSF14 | S100A10 | PLCD1 | PLA2G7 | ATP6V0A4 |
| FGFR3 | CA9 | HK1 | UNG | CRH | DYNC1H1 | DHPS | MOCS1 |
| SDHC | CCL5 | USP7 | TBK1 | FUCA1 | P4HA2 | PEX19 | APOA4 |
| VHL | GJA1 | HIP1 | PFKFB3 | TLE1 | KARS1 | KYNU | UNC119 |
| MDM2 | ERG | CSNK2B | KDM4C | CALM3 | CTSF | FPR2 | CASQ2 |
| CDC73 | DKC1 | PTGS1 | FUT2 | SLC25A13 | CDK13 | RORC | NR2E1 |
| SDHD | CUL1 | ENPP2 | RXRB | GOT2 | SELPLG | BCS1L | VIPR2 |
| FANCD2 | CD28 | CCNB2 | NTF3 | MAK | GCLM | SLC33A1 | ROBO4 |
| NRAS | CYP11B1 | PON1 | PPP1CB | SMARCC1 | HTT | FDFT1 | GAD2 |
| CASP8 | SF3B1 | EIF4G3 | ACSL4 | GDF2 | HRH4 | HAGH | GRK1 |
| FGFR1 | TUBB3 | TUBA1B | SMARCAL1 | TUBB2A | ABCA2 | PCSK2 | SLC4A4 |
| RAD54L | MAD1L1 | LOXL2 | SELENBP1 | CYBB | SLCO1B1 | LARS1 | HTR1B |
| NF2 | CBS | PTH | INHA | SLC31A1 | VAPA | PNMT | HTR4 |
| ERCC2 | RYR1 | ATF4 | PLA2G4A | PRDX3 | POFUT1 | PI4KA | MGAM |
| RUNX1 | GSN | GATA4 | WNT2B | ACKR1 | MARK2 | SLC25A19 | PRKAB2 |
| SRC | ANXA2 | ALOX5 | GNA13 | GGH | HSD11B1 | SPTLC2 | SNAP25 |
| ERBB3 | XRCC5 | TRAF2 | CPA1 | PGD | MAP4K2 | MMACHC | ECHS1 |

| BRCA2 | AURKB | AMACR | IRF8 | CUL2 | PGM3 | UGT8 | SLC26A3 |
|---------|-----------|---------|---------|---------|----------|----------|----------|
| PPM1D | MYCN | KRT17 | SREBF2 | PAX9 | MAP2 | ADRA1A | ACSS2 |
| TGFBR2 | GADD45A | ARHGEF2 | FABP3 | SET | RAP1B | FGB | NPY5R |
| ARID1A | IL3 | MT2A | KAT2A | FIG4 | RPL21 | MEF2A | GYPC |
| CHEK1 | SPARC | PFKP | TEAD1 | TNKS2 | CPE | POMT1 | CHRM2 |
| GREM1 | FGF7 | NR1I2 | ANXA3 | UCP2 | MVK | SERPINA5 | KCNQ3 |
| FANCA | BID | FZD7 | LEFTY2 | SHMT2 | MTMR2 | TLL1 | OSGEP |
| XRCC3 | GDF15 | PIAS1 | ITGA9 | SFTPB | TOLLIP | ALOX5AP | ISCU |
| EP300 | TFAP2A | CDC6 | ITGAX | TUBA1A | HARS2 | ATP6AP2 | ATP1A2 |
| ERBB4 | S100A4 | CALCA | PAICS | SLCO2A1 | TWNK | ISL1 | IDUA |
| POT1 | DKK1 | SLC3A2 | CSNK1E | HTRA2 | LMX1B | SEMA7A | TRPM6 |
| PIK3R1 | MMP3 | BMPR2 | BAG3 | CYB5R3 | CDK19 | NARS1 | BCKDK |
| CDK12 | ITGA6 | IL4R | DES | UBTF | ADGRG1 | KCNJ5 | ALDH6A1 |
| JUN | KLF5 | ISG15 | HSD17B4 | TNXB | NECTIN1 | ETFB | FBP2 |
| CDKN2B | CYP1A2 | PIK3R3 | CD81 | CFL2 | CERS2 | PSMD7 | SLC20A2 |
| CCNE1 | TNFRSF10A | DLL4 | FST | NUP107 | RRM2B | HINT1 | CHRND |
| ABCC1 | EIF2B5 | HPRT1 | FCGR3B | EPHX2 | FZD2 | NDN | TRAF3IP2 |
| STAT3 | TET2 | THBS2 | CHRNA3 | ACY1 | EPB41 | FDXR | CRYM |
| LZTR1 | IGFBP2 | NFATC2 | SAT1 | CBR1 | ACOX1 | LIPA | SLC1A7 |
| SMARCB1 | NAT1 | KCNN3 | PPBP | UBE2K | CD96 | DIAPH3 | CACNA1F |
| GATA3 | RAD21 | SP3 | FOXC2 | MERTK | UBE2D3 | GRID2 | LY96 |
| PRKAR1A | EXO1 | PROX1 | RETN | IGFALS | SAG | SCN9A | AKR1D1 |
| CYP17A1 | FAP | ADRB2 | CGA | AMBP | EIF2B1 | TLK2 | DPYS |
| FBXW7 | BAD | YWHAE | RAC2 | TAPBP | TUBA4A | CACNA1A | DTNA |
| MAP2K1 | TFRC | FYN | FABP7 | IRF7 | CCT5 | EHHADH | ARNT2 |
| WT1 | ENO1 | FPR1 | OXTR | TRIM32 | CHRM1 | PTDSS1 | STX1A |
| NTRK1 | TEK | RICTOR | CDC37 | SLC22A3 | USP2 | BCKDHA | SUOX |
| BUB1B | PRKCD | FOLR1 | GHRHR | NPY | PCCB | CCS | DLG2 |
| CYP19A1 | CTSB | EIF4G1 | HIPK2 | BMP3 | RAB7A | COL6A2 | SPTA1 |
| HMMR | BSG | SLC9A1 | TNFSF4 | NOD1 | ABCA4 | SLC26A2 | PDE10A |
| CDK2 | CEBPB | MELK | PAPPA | CASP5 | ERLIN2 | GRIK1 | P2RY12 |
| MAP3K1 | CRP | TXNRD1 | EPHA4 | OCLN | CHST3 | MAG | FGFRL1 |
| SUFU | NR1H2 | BTC | ENTPD1 | SLC28A1 | SP7 | ESD | MBTPS1 |
| BCL2 | GAPDH | CYP11A1 | TYRO3 | SUMO1 | C1S | MAOB | TACR2 |
| PGR | SOCS3 | MTAP | EHMT1 | AP3B1 | ITPKC | IL12RB2 | PDE9A |
| IL2 | IL17A | FGF5 | SSTR5 | DLG1 | HRH1 | C4BPA | MOG |
| EZH2 | HNRNPK | THY1 | TFEB | STING1 | CD1D | PSMB10 | C2 |
| NOTCH1 | PDK1 | TBL1XR1 | THRB | FAAH | UROD | ADCY1 | PTGDR2 |
| KRT19 | MPO | EIF4A1 | S100B | PTGIS | ATP6V0A2 | CTSG | AQP9 |
| CDKN1A | PPARA | PTPRG | CARD11 | TRADD | F10 | ATP6V1A | MYH6 |
| FANCG | RXRA | CXCR1 | HEY1 | OGT | ATXN10 | GCDH | PRPH |
| FOXA1 | MBD4 | PTPRK | FMR1 | TCP1 | IARS1 | NUP155 | CHRNNG |
| VEGFA | WNT1 | HDAC5 | RPS10 | GIPC1 | ARHGAP1 | ARHGEF6 | ITGA8 |
| NTRK3 | SBDS | CACNA1S | BRCC3 | HEXB | STK3 | BEST1 | KCND2 |

| BRCA2 | AURKB | AMACR | IRF8 | CUL2 | PGM3 | UGT8 | SLC26A3 |
|--------|----------|---------|---------|----------|----------|----------|---------|
| HIF1A | FADD | GAB1 | HNRNPC | SELP | HSPA1L | FCN2 | GJA4 |
| KMT2D | YY1 | CHD7 | LBR | TPMT | SLIT3 | BDH1 | TREH |
| SHC1 | TNFRSF1B | PRKCB | PLCE1 | PGAM1 | CCL7 | PTPN22 | FYB1 |
| ERCC5 | HDAC6 | ECM1 | CCL11 | PITX2 | CDC42BPB | SLC20A1 | GDA |
| FANCL | STAT6 | RPS6 | KRT1 | NOX1 | GPT2 | VLDLR | F9 |
| SMAD7 | CD34 | PRMT7 | RPLP0 | ANK1 | ATG16L1 | SLC52A3 | SNTA1 |
| PRKDC | BMP7 | VCP | PRKACG | ST3GAL3 | FKBP8 | PCK2 | SLC12A3 |
| WRN | SLC34A2 | CD163 | HYAL1 | PTPN14 | LETM1 | VKORC1 | MCFD2 |
| ERCC4 | ITGB3 | RPS6KB2 | CLIC1 | PLEC | STK36 | NDUFA8 | PDE6C |
| ITGB1 | E2F3 | UBC | AMFR | PCSK1 | WFS1 | TUBA8 | CHAT |
| IL1B | ANXA1 | RALA | ACLY | CD226 | ADAMTS13 | WASF1 | ADH4 |
| NTRK2 | IL2RA | MYBL2 | KPNA2 | TDG | PKLR | GALNT2 | CPT1B |
| TGFB1 | CASP7 | GAS6 | ROR1 | FGA | RIPK2 | AMT | AVPR1A |
| SMO | EGR1 | CD70 | ERCC8 | SYN1 | LDHB | POMGNT1 | MANBA |
| CREBBP | EIF4E | PRKCE | LPAR3 | CYBA | LTK | MLKL | COX6A1 |
| MUC1 | CCN2 | POMC | VDAC1 | DDIT4 | RAMP2 | PSMB1 | CACNA1E |
| HNF1A | KDM5B | EPHA5 | SPRY2 | HADHB | PINK1 | PREP | ST3GAL5 |
| RB1CC1 | PDCD1LG2 | HSPG2 | RNF216 | POLR1C | CES2 | CLCN1 | DAO |
| DLC1 | DSC2 | SATB1 | GDNF | PFAS | HPD | CNTNAP1 | EIF2AK1 |
| AIP | PLK2 | STUB1 | MDH2 | ATP12A | AK2 | DAB1 | NPR3 |
| PHB1 | NDRG1 | PTH1R | DRD2 | PPP1R3A | PMP22 | PDE1C | TRPV3 |
| MSR1 | SOX4 | PBX1 | NTN1 | CFH | DPYSL2 | BCKDHB | AMPD1 |
| BAX | BCR | NR3C2 | NCSTN | ATP5F1A | FOXG1 | ARSB | PDE6D |
| PPARG | FOLH1 | TCF4 | TTR | PFKL | OAT | APRT | PEX7 |
| MTOR | SYK | NRIP1 | FHL2 | TUBB6 | EPS15 | GRB14 | CHRNB1 |
| XPC | ITGAV | DPP4 | COL5A1 | GPHN | MAP4K4 | IL1RAP | GFRA2 |
| NCOR1 | ADAR | BIN1 | RALBP1 | KPNB1 | MYOF | OPHN1 | SCNN1G |
| AURKA | HMGA1 | F5 | ABL2 | MLXIPL | SLC25A1 | CD3E | SLC12A1 |
| MITF | HBEGF | GRM8 | DVL3 | GRK2 | MMADHC | JAM3 | CPA6 |
| ATRX | NCOA1 | MMP8 | RORA | CDC7 | MCCC2 | TDP2 | KCNJ12 |
| CD274 | ABCC2 | IRF4 | NONO | COL4A6 | AFG3L2 | CRHR2 | C9 |
| BCAR1 | GNA11 | DAB2 | ANG | AKR1C4 | LIMK2 | TRPM1 | HCCS |
| PHOX2B | CHUK | ARG1 | CRABP1 | POLE2 | NR1H3 | DMPK | SGSH |
| MAX | HDAC2 | AGER | KAT6A | GNB2 | CRHR1 | SLC6A6 | CAPN5 |
| NRG1 | VEGFB | MAP2K5 | GPNMB | PCSK7 | HEXA | MPI | GABRD |
| IGF1R | EPOR | LIMK1 | DHX9 | MAPRE1 | ENPEP | KCNJ1 | HTR7 |
| TSG101 | CCR7 | AKR1C2 | MAP3K20 | LYZ | CTSV | IMPA1 | GRM7 |
| MAP2K4 | THBS4 | ELANE | ATP1A1 | YWHAB | EXOSC3 | ATP6V1E1 | CC2D1A |
| HFE | CTNNA2 | TOP2B | NLRP3 | COL6A3 | BCHE | HMGCS1 | SCN8A |
| ERCC3 | JAG1 | SRSF2 | TSPO | SLC2A2 | PDP1 | IDH3B | ANGPTL3 |
| WEE1 | FSCN1 | SLC29A1 | TGFB1 | SNRNP200 | ALDH7A1 | MAN1A2 | PLP1 |
| SMAD3 | ALB | EIF2S1 | LAMC1 | CENPE | NR1I3 | CDKL5 | MTMR14 |
| KDM6A | PCSK9 | ESRRB | CRKL | AKR1B1 | FLII | DISC1 | ETHE1 |

| BRCA2 | AURKB | AMACR | IRF8 | CUL2 | PGM3 | UGT8 | SLC26A3 |
|---------|-----------|-----------|-----------|----------|----------|----------|-----------|
| ESR2 | LGALS1 | S100A9 | CALD1 | SLC17A5 | TUBB4B | LTBP2 | SCN4B |
| TGFBR1 | PPARD | CENPF | PSMB9 | COL4A5 | GLP1R | GRIK2 | CHRN2 |
| MAPK1 | POSTN | AKR1C1 | CYP2C8 | TAB2 | PI4KB | CAPNS1 | PPP3CB |
| DHFR | IDO1 | DDX41 | TLR3 | RNASE1 | GAD1 | SLIT1 | SLC18A2 |
| IL6 | LAMA5 | RSPO2 | TCF12 | RIPK4 | KCNK9 | ELOVL4 | CAV3 |
| FAS | ITGA3 | WNT7B | HDAC8 | SPTLC1 | CITED2 | NDUFA10 | NPHP1 |
| IGF1 | IL18 | LPAR1 | CILK1 | RIGI | CFP | SLC5A6 | C1QC |
| EGF | SOD1 | H3-3A | MADD | HGS | BHMT | SLC12A2 | DNM1 |
| TP53BP1 | CHGA | FCGR3A | CIITA | HNRNPDL | CNP | CKM | IDS |
| ABCB1 | CAT | ACP1 | NTSR1 | RAC3 | ATXN3 | PAFAH1B1 | DEGS1 |
| IDH1 | ANXA5 | RAP1A | UBE2N | COL6A1 | ATP2A3 | IMPDH1 | TPK1 |
| IL1RN | BIRC2 | ADAM9 | RPL18 | AARS1 | ADARB1 | ADCY2 | CORIN |
| KMT2C | SQSTM1 | HPGD | EFEMP1 | ATP6AP1 | PIIB | GAK | F12 |
| EXT2 | RACK1 | NR5A2 | CHD2 | ADGRE5 | GABBR1 | CELF2 | HTR1D |
| PBRM1 | MMP13 | ALDOA | IRF3 | ST3GAL4 | ETFA | SARS1 | CERS1 |
| RAF1 | CD40 | TYK2 | ASCL1 | TRPC6 | BCAT1 | ABCD3 | AASS |
| IGF2 | BDNF | HSD3B1 | AICDA | KRT6A | SCNN1A | GRK6 | AVPR1B |
| TP63 | JUP | SMC3 | KCNA3 | SERPINC1 | ALAD | CYP26B1 | GRIK5 |
| CXCR4 | CLU | DAXX | CA2 | UGDH | STK39 | PPID | QDPR |
| ABCG2 | GLI2 | MMP10 | UBA1 | TCN2 | FABP1 | RTN4R | SNCB |
| PTGS2 | BAG1 | EFNA1 | PSMC4 | DNM1L | NCK1 | TPP2 | GRIK4 |
| TNF | ESRRA | PEBP1 | RPS6KA3 | ACHE | PTPRS | DRD4 | PCK1 |
| PIK3CG | PXN | LTF | TAP2 | MUSK | YME1L1 | GP6 | GABRA4 |
| NQO2 | REV3L | ACE | BCL11B | HBB | SCNN1B | ETFDH | POMT2 |
| IL7R | CPS1 | REL | MAPKAPK2 | PURA | PSMD4 | NMNAT1 | NDUFA9 |
| KDR | RUNX2 | ANPEP | TPI1 | SFTPA1 | HTR2A | RIMS1 | ADCYAP1R1 |
| GPC3 | LOX | PLCG2 | NR2F2 | AVPR2 | NRG3 | GMPS | NOX3 |
| GSTM1 | EIF4EBP1 | SIX1 | LPP | ARCN1 | PRICKLE1 | SLC34A1 | RLBP1 |
| GATA2 | IGFBP1 | CYP2B6 | SMURF1 | GRIN2A | ACV2B | OGDH | AQP4 |
| CDKN1C | NOTCH4 | SULT1E1 | SALL4 | OPRM1 | MSRA | SLC10A1 | C8B |
| MKI67 | PAX5 | PRDX2 | HAND2 | UGT1A4 | LTA4H | IDH3A | SYT2 |
| JAK2 | TNFRSF1A | HLA-DQA1 | CAV2 | TUFM | RIPK3 | LRPAP1 | LAT |
| CDK6 | TNFRSF11B | HNRNPA2B1 | WDR5 | TNFSF13 | SCN4A | CD3G | ROM1 |
| XPA | NCOA2 | EPHX1 | GNB1 | GPC4 | EEA1 | NEFL | NAAA |
| FASLG | LCN2 | NR5A1 | EPHB6 | CNBP | LAMB2 | PTPRM | SEC24D |
| XRCC1 | STMN1 | ADIPOR1 | KIF11 | APPL1 | LRP2 | SALL1 | LOXL3 |
| PRKN | RRM1 | ROCK2 | FGR | COX4I1 | CD244 | ALDH5A1 | HCRTR2 |
| MMP2 | PIN1 | RPS6KA1 | TNFRSF13B | DPF2 | RXFP2 | CDK16 | ACADS |
| KMT2A | ENO2 | ATP6V0A1 | AIMP2 | DHCR24 | OPA1 | CASP14 | CACNB1 |
| CD44 | IGFBP5 | IFNA2 | IL1R2 | ALOX12B | PHKB | PHKA2 | MTO1 |
| IDH2 | MST1R | CP | MGP | ELP1 | BLMH | C1QA | NPC2 |
| PTPN11 | PTPRC | KAT5 | POLG | CYP27A1 | AARS2 | NDUFS3 | SCN3A |
| PARP1 | VRK1 | CRK | ITGA1 | MC2R | NPPA | PCBD1 | KCNQ2 |

| BRCA2 | AURKB | AMACR | IRF8 | CUL2 | PGM3 | UGT8 | SLC26A3 |
|---------|---------|---------|-----------|----------|----------|----------|----------|
| FLT1 | CUX1 | MCM7 | ATP7A | MAP1B | TNFRSF25 | SLC25A4 | KCNJ2 |
| MTHFR | ETV1 | BCOR | PBK | PSPH | PTGDR | PDK3 | GYS1 |
| NEK2 | PDPK1 | NRCAM | NHP2 | SLC5A1 | DLD | TUBB1 | JPH2 |
| MMP9 | TG | CASP6 | MAP2K6 | SIK1 | HBA1 | UNC13B | TRHR |
| ABCA1 | ACACA | PPP2CA | HNRNPU | AQP5 | ADSL | LPAR6 | PHOX2A |
| GSTP1 | F3 | HNRNPA1 | SMAD9 | PDE5A | MARK3 | MPZ | SLC6A8 |
| RASSF1 | PHGDH | PTPRF | HLA-DPB1 | TBXAS1 | ABCB6 | LOXL1 | GRM5 |
| PTCH2 | DUSP6 | WIF1 | UBE2D1 | TLR6 | PPP1CC | CALU | KCNK3 |
| SOD2 | IGFBP6 | MAP3K5 | COL7A1 | HCFC1 | ACAD9 | SLC1A2 | LIAS |
| NFE2L2 | GPC6 | SLC2A3 | FDPS | PIK3C2A | PEX14 | NFS1 | HPCA |
| NFKB1 | HMOX1 | HSPA1A | FZD5 | NEU1 | ATP2B3 | TNNT3 | XYLT1 |
| SMARCE1 | PDCD4 | ABI1 | DDB1 | CTNND2 | GNAI1 | AP2M1 | SLC2A9 |
| BIRC5 | CXCL1 | CRABP2 | KDM2B | ASS1 | MMP19 | NDUFS2 | SLC3A1 |
| LMNA | LATS1 | NR0B1 | RANBP1 | IL10RA | UBR1 | PTPN7 | KCNA2 |
| RNASEL | IKBKB | PER2 | HMBS | BRDT | AVP | SLC27A4 | CLN3 |
| DDB2 | GSTM3 | EEF2 | GPC1 | TNFSF15 | DUT | DRD3 | CDH8 |
| SPOP | FEN1 | FKBP4 | CHD3 | PLOD1 | AGRN | ANTXR2 | CNGA3 |
| CASP3 | HPSE | WNT7A | PAX6 | DST | RAB5A | COL4A4 | GPLD1 |
| NCOA3 | RHOB | PSMB8 | RPL10 | IFNAR2 | MAT1A | PEX2 | SCN7A |
| KLC1 | IKBKE | FGF18 | PRDM16 | TXNRD2 | LAP3 | PON2 | VNN1 |
| YAP1 | CYP24A1 | FURIN | MST1 | PLCB1 | STIP1 | KHK | KCNH5 |
| TFF1 | CDK7 | FLNA | PRKD3 | TUBB2B | PCCA | SLC25A10 | TMPRSS15 |
| GNAS | RYR2 | RPTOR | PLK4 | ADH5 | CCR8 | PSMB6 | MYL1 |
| MGMT | TGIF1 | MMP12 | UGT2B7 | SMYD2 | HDAC10 | APLP2 | GLRA1 |
| ACVR1B | H2AX | AMH | LPL | ABCB7 | MYH10 | ROBO2 | PDE6A |
| GLI1 | HK2 | CHD8 | LTBP1 | CEL | TRPM4 | KCNAB2 | PCDH19 |
| TYMS | HSPA8 | IL2RB | PICALM | SLC22A5 | KCNJ6 | SLC12A4 | GP1BB |
| FOXO1 | SOX10 | KREMEN1 | FGF23 | USF1 | ADCY6 | CNGB1 | ADRA1D |
| SOX9 | ITGB4 | CAMK2G | SIK2 | AP2S1 | VAC14 | DPP6 | SNCAIP |
| WWOX | STS | MECP2 | DGCR8 | NRF1 | RAD23A | DLG3 | HCRTR1 |
| CYP1A1 | MYLK | SPHK2 | WNK1 | TRIM21 | LOXL4 | STK24 | P2RX3 |
| IRF1 | PTPN1 | PFN1 | NOG | PTGER3 | EIF3F | PDE4C | NDUFB10 |
| KLF6 | ANGPT2 | HUWE1 | KRT10 | KRT13 | DOCK6 | MGAT2 | BPGM |
| ATRIP | NCAM1 | ARF6 | BPTF | DCLK1 | GBF1 | VAPB | NDUFA1 |
| FGFR4 | CD4 | CDK5 | PVR | PRKAR1B | DARS1 | ALG1 | KCNQ4 |
| CBFB | SFRP1 | FTO | PAK6 | SPG7 | GRIN2B | NDUFS4 | ARHGAP4 |
| AXL | AIFM1 | CKB | TNFRSF12A | GJB1 | KPNA1 | GPD2 | P2RX4 |
| ITCH | TRPS1 | FZD3 | TRPM8 | CD5 | CRY1 | MYH3 | AQP2 |
| PHB2 | XRCC4 | CSTA | HYOU1 | PTS | CSTB | C1R | KMO |
| KLK3 | TXN | SELE | CTRC | SIRT5 | ERAP1 | CACNA1B | PON3 |
| CXCL8 | DCK | PRDX6 | HELLS | MAPKAPK3 | AIMP1 | PLOD3 | ALS2 |
| AKT2 | ILK | TRPC4 | CST3 | TNFSF13B | ADCY3 | LRP8 | SERPINI1 |
| STAG2 | HLA-G | CYP2C9 | TARDBP | PDHB | RAB11A | SLC27A2 | RASGRP2 |

| BRCA2 | AURKB | AMACR | IRF8 | CUL2 | PGM3 | UGT8 | SLC26A3 |
|----------|-----------|---------|----------|----------|----------|---------|----------|
| IGFBP3 | TYR | SMURF2 | FSHB | WNT10A | SLC6A4 | ACAN | ACAT2 |
| DNMT1 | TNFRSF11A | GSR | COL4A1 | SH3GL1 | HERC2 | MID1 | PGAM2 |
| SOX2 | CDH13 | ATG5 | PARN | PTGDS | CTH | ZIC1 | ALDH4A1 |
| ZEB1 | B2M | PRKCQ | RFC1 | HTRA1 | LTB4R | VDAC3 | CLCN2 |
| CTSD | MSLN | ITGB2 | LAMB3 | KAT8 | RNASEH2A | NT5C3A | CACNA1I |
| SMAD2 | CSNK2A1 | NSUN2 | LMNB1 | ITGB5 | HDAC11 | TUBB4A | DPP10 |
| PRLR | LRP6 | POU2F1 | AKR1B10 | PDHX | DIAPH1 | UQCERS1 | ALAS1 |
| TCF7L2 | KCNQ1 | PRKD1 | FZD1 | POLR3B | PLCB3 | EN2 | KCNC3 |
| ERCC1 | TUBB | ACVR1 | CLTC | SEMA3C | MSX1 | SLC1A3 | TPH2 |
| CEBPA | ADAM17 | LAMC2 | GC | HDC | PUS1 | GNAL | SYNJ1 |
| RARB | DDX5 | TWIST2 | CD247 | ADORA2A | MOGS | MYT1L | SPR |
| TBX3 | ABCC3 | TRIM25 | ELN | ACAT1 | TNFRSF21 | OPRD1 | KCNC4 |
| CCND2 | TGM2 | MATK | EEF1A2 | SLC16A7 | MYOCD | ALAS2 | KCNJ10 |
| VDR | SYP | PRMT5 | SRF | H6PD | NSDHL | GNAT2 | AGA |
| DNMT3A | CADM1 | CSF3R | IREB2 | NIN | GRK5 | NDUFS1 | IL5RA |
| LEP | TKT | LAMP1 | OFD1 | POLL | GALNT3 | PNPT1 | CHRM4 |
| PLAU | TMEM43 | UMPS | EPHB3 | MAN1B1 | STXBP2 | SLC22A2 | OXCT1 |
| PDGFRB | DUSP1 | MCM4 | EFNB1 | AGTR2 | DSC3 | SLC22A4 | CSRP3 |
| SETD2 | PRKAA1 | CCR6 | SERPINH1 | KLK1 | NEK1 | CFD | ZIC3 |
| PCNA | FOSL1 | SLIT2 | EPHB1 | GRIA3 | CYP11B2 | SNAP23 | ABCA5 |
| ROS1 | AKR1C3 | TFE3 | ID2 | EMD | MKNK1 | DTYMK | KCNE1 |
| IFNG | VTN | MALT1 | RPL35A | TRPV1 | LONP1 | ADRA2C | FMO3 |
| NKX2-1 | TCF3 | CDK8 | RPA2 | OTX2 | CANT1 | ADRA1B | CACNB4 |
| TWIST1 | IKBKG | CYSLTR1 | DHCR7 | PRIM1 | IL23R | GNAT1 | CLCN4 |
| AXIN1 | IL15 | CIB1 | PTPN2 | NCF4 | PADI4 | CNTN1 | RORB |
| CTLA4 | IL6R | MMP15 | TPT1 | TNFRSF18 | CHRM3 | SORD | AGXT |
| CDK1 | CDC25B | STIM1 | TPO | SMPD1 | PPP2CB | STX4 | DAGLA |
| KRT7 | ITGA2 | PSMB5 | HADHA | UNC13D | FERMT3 | WNK4 | CLCNKB |
| FLT4 | CD80 | TERF2 | HNRNPD | SPI1 | NOS1 | ZIC2 | ACAD8 |
| CASP10 | GPX1 | FKBP5 | SOD3 | KNG1 | TCIRG1 | ADRB1 | CPN1 |
| FHIT | MCM3 | MYH14 | CD2 | IL9 | ASL | ALDH3A2 | COX15 |
| NAT2 | DAPK1 | NFIB | MYOD1 | METAP2 | FBLN5 | STXBP1 | NCAN |
| SP1 | GATA1 | FGF13 | ERN1 | SLC11A2 | FECH | RPS6KA4 | SLC22A12 |
| RIPK1 | CEACAM3 | SFRP4 | CDA | PDE4D | MAP3K12 | NPR2 | KCNE3 |
| AKT3 | CYP2E1 | HSD17B3 | GSK3A | IL2RG | SCO2 | MTM1 | ADRA2B |
| TOP2A | TLR9 | PRKCZ | PLCB4 | GANAB | GRIN2D | PRKG2 | GP9 |
| LDLR | WNT3 | EIF3A | DFFA | TBX5 | ICAM2 | PDE4B | MYH2 |
| GSK3B | MYBPC3 | PPP1R1B | ATIC | TLR1 | SLC26A4 | PSTPIP1 | GALM |
| CACNA2D1 | ADAM12 | MPL | EIF4A3 | RPS6KA2 | DOCK2 | CARD9 | BST1 |
| KEAP1 | ST14 | FABP5 | ACO2 | MS4A1 | GARS1 | CYP51A1 | PTGIR |
| BSCL2 | EWSR1 | CD19 | SUV39H1 | FOLR2 | CDON | FGD4 | SLC6A1 |
| DCC | HSP90AB1 | PGRMC1 | HCLS1 | MBP | GRIN1 | SLC1A4 | GJA8 |
| IRAK4 | HSPA9 | SMC1A | PTBP1 | SLC7A7 | PITX1 | PPP3CC | SLC25A20 |

| BRCA2 | AURKB | AMACR | IRF8 | CUL2 | PGM3 | UGT8 | SLC26A3 |
|----------|----------|----------|---------|---------|----------|---------|----------|
| PAH | HAVCR2 | ITGAM | FER | RNF2 | APOA2 | BCAT2 | ATP2A1 |
| VEGFC | PTPRJ | TRIO | PPIA | APH1A | CTSC | GLDC | APOC2 |
| E2F1 | CXCR2 | CDT1 | COL4A2 | RACGAP1 | DHODH | CDK5R1 | FCN3 |
| PDCD1 | LYN | SPINT2 | KL | PCNT | ANXA6 | PSENE1 | TSPAN7 |
| BCL2L1 | PRMT1 | YWHAQ | ABCC6 | RUVBL2 | ADCY9 | DBI | SCN2A |
| JAK1 | KLK6 | IFI16 | MAP2K7 | PRKCH | ARPC1B | KCNE2 | CTNS |
| RHOA | SCN5A | KDM3B | HSD11B2 | ARG2 | MFN1 | CA1 | ADAMTS10 |
| EXT1 | U2AF1 | CSNK1A1 | PSMA1 | AQP1 | ATXN1 | TPSAB1 | SLC13A5 |
| HGF | SFN | PTPN13 | ICOSLG | AHSG | CHL1 | GPD1 | GALE |
| HSP90AA1 | ARNT | GLO1 | AURKC | FBN2 | MYL9 | AQP7 | HGD |
| CAV1 | MTRR | ESRRG | VAV3 | FLRT3 | ADK | B3GAT3 | PPP3R1 |
| DROSHA | IL7 | GAB2 | SIRPA | EFEMP2 | CNR2 | NR1D1 | F11 |
| MMP1 | HABP2 | ALPP | GGT1 | SCARB2 | FAH | KIF1A | S1PR5 |
| IL10 | TNC | GABRA6 | LMO2 | FCGR2B | ACTA1 | DBT | HBG2 |
| SRD5A2 | LIFR | TMPO | CYP21A2 | TRAP1 | ME2 | NARS2 | MCHR1 |
| FGF2 | MDC1 | CCR1 | SIRT7 | ACVRL1 | SURF1 | GM2A | ENPP3 |
| ENG | MECOM | ARHGAP26 | PTK7 | DOCK1 | NEUROD1 | CHN1 | GABBR2 |
| TNFSF10 | MYH9 | GFAP | HLA-DRA | ACTG1 | VAR1 | TSE1 | SCO1 |
| PTK2 | PRKAG2 | SLC7A5 | TLR5 | ATP2C1 | UBE2D2 | CNTNAP2 | CASQ1 |
| MMP14 | TRAF3 | TAB1 | PAX3 | PABPN1 | IRF9 | RCAN1 | NLGN1 |
| NSD1 | COL1A1 | IFNGR2 | PDHA1 | USP10 | GZMA | YARS1 | CYP2U1 |
| CYP1B1 | WNT10B | PKN1 | RAB27A | IRF5 | LIPG | RDH5 | SEPSECS |
| ABL1 | MYD88 | TRAF6 | SOST | LAMP2 | CSF2RB | CPB2 | IL31RA |
| BMP6 | DLL1 | SMAD1 | ASPH | ALDH1A2 | CD3D | PPT1 | LTC4S |
| CBL | TNNT2 | GRM1 | PNPLA6 | GSTO1 | CR1 | POLR3F | HCN2 |
| CEACAM5 | NCL | GNGT1 | APP | PIK3R4 | UQCRC2 | HTR1A | NPC1L1 |
| TGFA | CD9 | STK4 | BCL11A | REN | GBE1 | NDUFV2 | CLCN5 |
| CD82 | ANGPT1 | COL18A1 | MAP3K11 | PIK3R5 | GCK | PROC | NPHS1 |
| CSF3 | APOD | SRSF1 | SEMA4D | NR2C2 | DUOX2 | APBA2 | GJB3 |
| STAT1 | HAS2 | IRF2 | PSAP | DDX1 | POU3F2 | SLC11A1 | PTH2R |
| RELA | SLC16A1 | MTHFD1 | P4HB | LAMA1 | PKD2 | ADAMTS4 | ACTN2 |
| SNAI1 | SHMT1 | VASP | UBA2 | ALDH3A1 | SYT1 | APOH | GRAP2 |
| HDAC1 | KAT7 | FOXP2 | TAGLN | VAMP2 | TPP1 | UGP2 | GATM |
| HNF1B | SDC1 | VAV1 | NTF4 | TOP3A | PRTN3 | MMP20 | COX10 |
| NQO1 | RRM2 | LRRK2 | USP8 | EIF2AK4 | FA2H | HADH | GRM2 |
| PRF1 | SERPINA1 | EDNRB | EGLN3 | ANK3 | PTGES3 | PI4K2A | GK |
| MCL1 | DIABLO | EDN3 | ULK1 | F2RL3 | PPOX | IL17RA | CA14 |
| CASP9 | APOE | NSD2 | SEMA3E | NECTIN2 | PSMC3 | COL9A1 | SGCD |
| ERCC6 | IQGAP1 | RHO | ORAI1 | GHSR | PRKCSH | AGL | CACNG2 |
| CXCL12 | LCK | CA12 | CAPN2 | ALPL | GNPAT | KCNA4 | GABRG3 |
| BUB1 | PKP2 | TF | MMP16 | CRYAB | POLA1 | ADD1 | P2RX2 |
| DSP | MAP3K8 | IKZF1 | LAMA2 | DYRK2 | CD209 | KPNA3 | MEGF10 |
| NME1 | PIM1 | SPRY4 | ARRB2 | LCT | SERPINF2 | RNASEH1 | UPB1 |

| BRCA2 | AURKB | AMACR | IRF8 | CUL2 | PGM3 | UGT8 | SLC26A3 |
|----------|----------|---------|---------|---------|----------|---------|----------|
| MAPK3 | NGF | CRAT | ASAH1 | TDP1 | CA4 | MMAB | GALR3 |
| PRKCA | PTPN6 | ADAM10 | TACR1 | FZD6 | HSPA2 | CTSZ | SLC1A1 |
| ATP7B | CDH5 | INPPL1 | NIPBL | KCNN4 | NLGN3 | CLCN6 | UMOD |
| ACTC1 | INHBA | CALM1 | FGF14 | KCNMA1 | EIF2B2 | ASIC2 | SLC18A1 |
| ZFHX3 | CLDN1 | MMUT | PPAT | CASK | MAP3K3 | DLX5 | SLC6A19 |
| ETV6 | SUZ12 | HP | RPS6KA5 | PTPRN2 | DDOST | NPR1 | GABRA2 |
| AHR | LIF | PRKCI | ITPR3 | AIRE | ABCG1 | CETP | MYBPC1 |
| NPM1 | GJB2 | UGCG | CD74 | SORL1 | IVD | RHOT1 | SGCG |
| MAPK10 | NGFR | NNMT | TNKS | LTBP4 | PIP4K2A | TOR1A | SCN2B |
| DPYD | CD46 | GNB3 | GCLC | EZH1 | CHSY1 | ROBO3 | PLN |
| EFNA3 | CUBN | UBE2C | GP1BA | HRH2 | MARS1 | RPE65 | DGKD |
| FOXO3 | CSK | TACC3 | WNT11 | SLC22A1 | HSD17B10 | NAGA | TPH1 |
| PTGFR | TNFAIP3 | PKD1 | PLA2G6 | FGF12 | PSMD2 | DRD1 | MYL4 |
| FN1 | RELB | ABCC5 | DYRK1A | ANP32A | NAE1 | RHAG | GPR37 |
| MAPK8 | CD8A | FOXL2 | TLR7 | ACTN1 | PRODH | ITPA | GABRB3 |
| TPM1 | IL6ST | XDH | PTGER2 | IL11RA | GAA | SCN3B | GYG1 |
| OGG1 | PLA2G2A | PTGER4 | CLDN18 | TGM1 | PDXK | AOX1 | GRIA2 |
| SNAI2 | CARM1 | SOX5 | CX3CR1 | A2M | COPB2 | MLYCD | KERA |
| TRIM24 | EDNRA | CD79A | GART | C5AR1 | PRKAG1 | DNAH11 | ENTPD2 |
| COMT | GRN | HTR2C | SIRT2 | CHRN4 | HTR3A | SUCLG1 | SLC7A9 |
| VIM | PTPRD | ST3GAL1 | CD14 | NR4A3 | CDH15 | LCP2 | GAMT |
| TP73 | SERPINB2 | USP9X | MAPKAP1 | MATR3 | P2RY1 | SLC12A7 | CYP4F2 |
| IGF2R | CYP3A5 | PRDM1 | PAX2 | NLRP1 | MYLK2 | GCGR | PDHA2 |
| RARA | HSF1 | NME2 | ABCA3 | APTX | PYCR2 | C1QB | GABRR1 |
| NFKBIA | TGFB3 | C3AR1 | HGFAC | TBX21 | ZYX | DNAJB2 | KCNN2 |
| SNCG | CTBP1 | TNFRSF4 | MCM6 | COL4A3 | MED23 | CYP7B1 | ATP6V1B1 |
| STAT5A | EIF2AK3 | FLNB | FZD4 | CSF2RA | MCCC1 | LMAN1 | SLC6A13 |
| CCND3 | CCNA1 | CXADR | AGPAT2 | C4A | PSMA6 | SLC19A3 | GLRB |
| ZEB2 | MYO7A | YWHAZ | CD22 | KIF2A | ELOVL5 | MTNR1B | GRIN2C |
| TOP1 | EHMT2 | RPL11 | EFNB2 | CA8 | PSMA5 | HMOX2 | GABRA5 |
| ODC1 | NRP2 | KCNJ4 | ST6GAL1 | ARHGEF1 | GALC | TEC | IL1RAPL1 |
| MYH11 | NHERF1 | NDUFA13 | ORC1 | IFIH1 | SRPK2 | PGM1 | APOA5 |
| TYMP | NT5E | NUP214 | MSX2 | SATB2 | CRYAA | ADD3 | KCNC1 |
| EPHB2 | ATF3 | BMPR1B | IMPDH2 | USP14 | LRAT | TXK | SLC26A5 |
| SLC2A1 | VCAN | KDM6B | CR2 | RCC1 | P4HA1 | CLEC7A | CA5A |
| SERPINE1 | WNT4 | SH2B3 | ALDH1A3 | SULT2B1 | TANK | SLC6A5 | P2RY11 |
| MAPK14 | MIF | AGT | STAR | CPOX | CD33 | BLVRA | CHRNA6 |
| SOS1 | PLAT | THRA | SAMHD1 | AOC3 | PDE8B | CAPN3 | SLC32A1 |
| PIK3CD | TFDP1 | SLC2A4 | TALDO1 | P2RY2 | TYROBP | CARTPT | GABRB1 |
| PPP2R1B | SPHK1 | DLK1 | SENP1 | ABCA7 | PLIN1 | RPIA | SLC1A6 |
| RBBP8 | SKP1 | CPT1A | PRKG1 | DLAT | GRK3 | DDC | PRSS12 |
| PPP2R2A | TK1 | NAA10 | SIAH1 | FZD9 | PLOD2 | ABAT | P2RX1 |
| RPS6KB1 | HDAC3 | EGLN1 | CYB5A | ACE2 | ALPI | SARDH | SLC9A6 |

| BRCA2 | AURKB | AMACR | IRF8 | CUL2 | PGM3 | UGT8 | SLC26A3 |
|-----------|----------|----------|---------|----------|----------|---------|---------|
| CSF1R | GMNN | SERPINA3 | PRKD2 | PAK5 | HMGCS2 | SLC39A8 | GYS2 |
| ICAM1 | DDIT3 | FABP4 | HNRNPH1 | TRPV4 | RBP4 | SLC12A6 | HTR1F |
| FOS | HSP90B1 | PRDX1 | TLN1 | GCG | PIGA | CHMP4B | DCX |
| BIRC3 | GPI | ALOX12 | TRPV6 | POLR1A | ITGA7 | UQCRC1 | KCNT1 |
| FOXM1 | FGF17 | KDM5C | PNKP | MGLL | CYP46A1 | CTSA | SLC18A3 |
| RAC1 | TIAM1 | DAG1 | USP1 | FXN | DPEP1 | COX6B1 | NPY2R |
| CTCF | LIG1 | SETDB1 | LMNB2 | MARK4 | AGPS | DARS2 | HCN4 |
| EPHB4 | PTPN12 | GNE | SFPQ | APLNR | NLRC4 | DLG4 | SLC22A6 |
| RRAS2 | NEK9 | ACP5 | JAG2 | CAPN1 | LARS2 | DUOX1 | MSMO1 |
| RPS20 | TRIM28 | PCBP1 | TBP | SMAD5 | RAPGEF3 | SLC12A5 | GLRA2 |
| MAP2K2 | AMPH | TMPRSS6 | ANXA11 | GUCY2D | RNMT | NDUFA6 | CELA2A |
| DNMT3B | CTSK | CBLB | GAL | SQLE | MYO9B | CBLIF | KCNJ8 |
| INSR | FUS | COL1A2 | P2RX7 | ALDOB | EXTL3 | GRM4 | |
| CASR | ROCK1 | SEMA4A | COL17A1 | SI | SLC4A1 | AMPD3 | |
| PTHLH | ACTN4 | ABCB11 | CANX | G6PC1 | SV2A | OCRL | |
| SPP1 | CUL3 | DNASE1 | HAX1 | CACNA1D | GALT | PIP5K1C | |
| SKP2 | APAF1 | CD79B | RPS3 | C3 | STT3B | PLAA | |
| POLK | G6PD | CNTFR | ZBTB16 | EEF2K | ADORA3 | BTD | |
| PRL | FOXP1 | ATF2 | CLOCK | PDK4 | FARSB | VPS35 | |
| PLK1 | FGF9 | AHCY | OCA2 | DDX6 | GABRA3 | DGKA | |
| IRS1 | MAP3K7 | CTSS | F7 | GUCY2C | CALCRL | C4B | |
| ABCC4 | ITGA5 | HSPB8 | MEFV | SERPINB6 | SERPINA6 | ENO3 | |
| PIK3R2 | HES1 | CCKBR | GPT | TREX1 | KCNA5 | ABCC8 | |
| CCNB1 | IGFBP4 | DVL2 | MYO5A | CCKAR | GNB5 | CLCN3 | |
| ACTB | LTA | CDC45 | ATP2A2 | COQ8A | SEC63 | ASIC1 | |
| PKM | HLA-DRB1 | DNAJB1 | RELN | FXR1 | CIT | TARS2 | |
| PLAUR | MAF | RPL5 | ATF6 | SDC2 | NFIA | TRPC3 | |
| FASN | FOXC1 | DUSP3 | RPN1 | SYNGAP1 | D2HGDH | SLC5A7 | |
| TNFRSF10B | HLA-DQB1 | CD58 | KDM4A | COMP | LFNG | DGAT1 | |
| NOTCH2 | CXCL10 | TRIM33 | MCM5 | IL21 | CFB | PNLIP | |
| MC1R | CDC20 | RAD23B | RPS17 | PSMD14 | GOLGA2 | ATP6V0C | |
| SLC19A1 | MAD2L1 | ANO1 | PEPD | BDKRB2 | PTPRN | ACADVL | |
| PDGFB | ADH1B | TUBG1 | AKR1A1 | GFPT1 | KIF22 | NRXN3 | |
| XIAP | IL13 | GLB1 | RPL10A | CASP4 | OPTN | NKX2-5 | |
| TIMP1 | F2R | BUB3 | CAMKK2 | ITIH4 | MAN2B1 | ACADSB | |
| TGFBR3 | CTSE | RPS14 | IHH | WARS1 | UFD1 | SLC16A2 | |
| TGFB2 | RASA1 | APOA1 | ZAP70 | PSMA3 | GNMT | ARL3 | |
| CFTR | RPSA | RPS19 | SIAH2 | FLNC | UCP1 | HMGCL | |
| APEX1 | OSM | PSAT1 | RNF168 | TUBA1C | PNPO | TTBK2 | |
| CYLD | SLC25A15 | LIG3 | GBA1 | ITGA2B | FCGRT | NPY1R | |
| KRT5 | HNF4A | IL17RD | PRKCG | CLPB | KIF5A | FBXO7 | |
| PTPN3 | GPX4 | USP15 | EFNA5 | ARF1 | CHKB | DBH | |
| MED1 | HMGCR | MAP3K14 | FES | DSG1 | SLC25A3 | ABCD1 | |

| BRCA2 | AURKB | AMACR | IRF8 | CUL2 | PGM3 | UGT8 | SLC26A3 |
|---------|---------|---------|--------|----------|----------|----------|---------|
| FGF3 | GRB7 | S1PR2 | TRPM7 | CCR4 | APOC3 | GNS | |
| CYP2D6 | BTK | RIT1 | FCGR2A | DPAGT1 | VAR2 | NEFH | |
| AREG | SMARCA2 | LGR5 | PABPC1 | ARHGDI1 | UCHL3 | SLC29A2 | |
| NOTCH3 | ATF1 | MINPP1 | MAT2A | ENDOG | SLC5A2 | GIPR | |
| MMP7 | CD276 | TPM2 | DPM1 | EMX2 | DMP1 | KCND3 | |
| TSHR | CAST | VIPR1 | MAP3K2 | PPP2R2B | PRSS3 | NCS1 | |
| HSPB1 | TERF1 | GUSB | PMEL | ACSF3 | PPP3CA | KCNK1 | |
| PAK1 | PDGFA | TAP1 | BGN | HIF1AN | LITAF | SYCP3 | |
| HDAC4 | SSTR2 | RPL26 | TPM3 | EPS8 | PIK3C2B | ADCY7 | |
| KRT8 | CYP2C19 | YES1 | DLL3 | NRG2 | PTPRZ1 | ACTG2 | |
| SOCS1 | CDH23 | KDM5A | SKI | DCTN1 | CNTN2 | M6PR | |
| FBN1 | IFNB1 | CHD4 | PLD2 | CLCN7 | GDI1 | NDUFV1 | |
| KDM4B | BTRC | RANBP2 | C1QBP | ASPA | MPDZ | TNNT1 | |
| CDKN2C | TNFRSF9 | CD27 | ITK | TXN2 | GRIK3 | PDE2A | |
| CREB1 | GZMB | TFPI | NHEJ1 | EYA1 | PDE4A | LPA | |
| HMGA2 | CCR5 | RUVBL1 | MYO6 | MEF2D | VDAC2 | GCNT2 | |
| CYCS | GH1 | CD63 | MIB1 | CLIP1 | EIF2B4 | KIRREL3 | |
| PIK3CB | RARS1 | NR2F1 | ABCB4 | NUP62 | PHKG2 | GRM3 | |
| KRT18 | MAPT | TTN | COL2A1 | ARSA | LRP4 | MASP2 | |
| COL3A1 | LHCGR | IL3RA | IL12B | BMP5 | TFR2 | PMPCB | |
| CCNA2 | CYP27B1 | FKBP1A | TBXT | PSMC1 | GDF11 | GDAP1 | |
| CDH3 | SSTR1 | GAPDHS | KCNH1 | DPP9 | NPPB | SLC2A10 | |
| MDM4 | TJP1 | MAPK11 | ITPR1 | BNIP3L | ATP1B1 | SERPIND1 | |
| IL4 | MSN | CUL4A | LAMB1 | NCF1 | DNM3 | PCYT2 | |
| KLF4 | SRGAP1 | TIE1 | PRNP | PYY | PDCD6IP | PDE6B | |
| CSF1 | SEMA3A | KLK4 | MAOA | PPP2R5D | TAT | NRXN1 | |
| LEPR | MYL3 | CIC | GRB10 | SLCO1B3 | ALDH18A1 | NDUFB9 | |
| TIMP3 | RBBP4 | BCL2L2 | MAPK13 | TREM1 | BLK | IRAK3 | |
| DDR1 | DOT1L | FUT8 | ASNS | COPA | NDUFS8 | AP1B1 | |
| E2F4 | WNT3A | CHRNA5 | SRPK1 | SCP2 | GFER | ATP13A2 | |
| BAK1 | S100A8 | IL12RB1 | SPTBN1 | SLC25A11 | OLR1 | GMPPB | |
| GRB2 | SRD5A1 | RPA1 | PSMA7 | TFAM | SIGMAR1 | ADAMTS5 | |
| CSF2 | DCN | CISH | TACR3 | DLST | B3GAT1 | HLCS | |
| ACTA2 | CCNE2 | FOSB | RPL35 | FADS1 | FHL1 | XYLT2 | |
| CDC25A | RHEB | MMP17 | GGPS1 | NR4A2 | ADORA2B | GRIA4 | |
| TLR4 | NUMA1 | GABRB2 | ABCB5 | TH | ALG8 | SLC14A1 | |
| BMI1 | NR4A1 | NEDD4 | IRAK1 | LNPEP | SUCLA2 | ACOX2 | |
| XBP1 | L1CAM | SIN3A | PTPRA | DCLRE1C | DNAJC6 | SLC6A2 | |
| KITLG | RBL2 | PARP2 | LAMA3 | CRBN | B4GALT1 | PYGM | |
| STAT5B | MAPK9 | POR | NT5C2 | CYP2R1 | LHX3 | PICK1 | |
| PPP2R1A | CD55 | SLC6A9 | PROS1 | NPC1 | UBE2A | RGS10 | |
| MYB | CSNK1D | ADNP | ITGAL | NFATC3 | COASY | GFM1 | |
| CCL2 | PXDN | RDX | PDGFD | DYSF | NLRP2 | ADRA2A | |

| BRCA2 | AURKB | AMACR | IRF8 | CUL2 | PGM3 | UGT8 | SLC26A3 |
|----------|--------|---------|---------|-----------|----------|--------|---------|
| PRKACA | TNNI3 | EEF1A1 | PRPS1 | MFAP5 | ARX | BACE1 | |
| INS | VCAM1 | COL11A1 | EPRS1 | PPIF | EIF2S3 | NFASC | |
| ETS1 | POLB | PIM2 | PRKAR2B | HAMP | AK1 | CHRNE | |
| THBS1 | CD47 | AMHR2 | ENPP1 | CD2AP | GSS | DGUOK | |
| EPHA2 | RBX1 | LRP5 | SCARB1 | CALM2 | CMA1 | GJA5 | |
| WNT5A | MYL2 | SLC13A3 | PNP | AQP3 | SERPING1 | NDUFS6 | |
| DSG2 | CXCR3 | CAD | INPP5D | PAK3 | FIBP | TBXA2R | |
| POU5F1 | SLC1A5 | NECTIN4 | SLC16A3 | ADCY8 | YARS2 | SCN10A | |
| NOS2 | PSEN2 | KAT6B | CX3CL1 | NCF2 | DGKZ | DGAT2 | |
| NCOR2 | IGFBP7 | HPN | NR1H4 | SLCO2B1 | CPT2 | PRCP | |
| MTR | GLS | ENTPD3 | RASGRP1 | EFNA4 | CFI | TREM2 | |
| BMP4 | CUL4B | NUP98 | ADAMTS1 | MDH1 | IL21R | RARS2 | |
| SHH | ROR2 | PRKACB | TCL1A | PFKM | ATP2B2 | COQ7 | |
| REST | SLC5A5 | SIRT3 | EIF4B | GNB4 | PDYN | TRPA1 | |
| PML | CHI3L1 | THPO | SSTR3 | FTL | KCNQ5 | HARS1 | |
| FLT3 | CD86 | VWF | NOX4 | PANK2 | CAMK2A | CRADD | |
| AGO2 | ADA | PKD2L1 | FBL | ITGB7 | SNRPN | EPX | |
| LEF1 | CCR2 | ITGA4 | POLI | CACNA1C | SEC24C | ABHD5 | |
| MED12 | PGK1 | UCHL1 | BLNK | SLC40A1 | PMM2 | PZP | |
| MME | CCK | TFG | WAS | ITM2B | MAPKAPK5 | NGLY1 | |
| SERPINB5 | CD59 | PRSS8 | TAF1 | SLC29A3 | NNT | PANX1 | |
| PTK6 | AFP | VIP | IFNGR1 | LPIN1 | TAOK1 | KCNJ11 | |
| CDH2 | EPHA1 | IL5 | TAL1 | PTPRU | GCH1 | ENTPD5 | |
| PTK2B | TTK | PARK7 | STAT2 | ADRB3 | PDE3A | SARS2 | |
| ALDH1A1 | GLI3 | EIF5A | PAX7 | TNFRSF13C | LCAT | CNGA1 | |
| SIRT1 | UBE2I | PRDX5 | FZR1 | RTN4 | PYGL | FCER2 | |
| LDHA | GFRA3 | PRKAA2 | SLC6A3 | COL5A2 | PMPCA | PHYH | |

Supplementary Table 4: Docking scores of Sitogluside to high scoring hub gens in PPI network using Dockthor online tool.

| Rank | File ID | Ligand-Receptor | Affinity | Total Energy | vdW Energy | Elec. Energy |
|------|------------|-------------------|----------|--------------|------------|--------------|
| 1 | e40d8dea56 | Sitogluside-STAT3 | -9.092 | 492.643 | -23.017 | -13.051 |
| 1 | bb0d8fba57 | Sitogluside-SRC | -7.935 | 493.097 | -17.279 | -19.131 |
| 1 | fbc798577c | Sitogluside-MAPK1 | -8.400 | 491.778 | -19.483 | -18.958 |